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The objective of this study was to modify the physicochemical properties of two common 
drugs via supramolecular derivatization. Sulfasalazine is a powerful anti-inflammatory drug 
and fluconazole has a strong antibacterial and antifungal activity. The common feature is 
their very low solubility in water. Cyclodextrin (CD) inclusion complexation and co-
crystallization were carried out with the aim of ultimately improving the bioavailability of 
both drugs. Each new crystal phase isolated was analysed using X-ray diffraction, thermal 
and spectroscopic techniques. 
Sulfasalazine presents two tautomeric forms which were isolated using different preparative 
methods via recrystallization from different solvents. Each form was used in combination 
with nine different co-formers in attempts to form co-crystals. This approach yielded 
negative results. Cyclodextrin inclusion complexation of sulfasalazine was studied with a 
variety of cyclodextrins (α-CD, β-CD, γ-CD, dimethylated β-CD and permethylated β-CD). 
The complexation attempts yielded an inclusion complex between one of the tautomers of 
sulfasalazine and γ-cyclodextrin. No single crystals were obtained and hence it was 
impossible to resolve the crystal structure. However, it was possible to analyse the complex 
thermally and spectroscopically.  
The co-crystallization of fluconazole with biocompatible co-formers was not investigated 
due to the appearance of extensive previous reports on its co-crystal formation in the 
literature. Thus, only cyclodextrin inclusion complexation (with the same CDs listed above) 
was studied. Three inclusion complexes with native CDs were successfully prepared. Two 
crystallographically distinct complexes of β-CD with fluconazole as guest having 2:1 host-
guest stoichiometry were isolated. While these two hydrated complexes had been identified 
recently by previous researchers and the X-ray structure of one of the crystal forms had been 
partially resolved, their characterization was incomplete. In the present study, significant 
advances on the previous work included the complete X-ray structural resolution of both 
crystal forms, designated TBCDFLU (triclinic) and MBCDFLU (monoclinic), as well as a 
systematic study of the conditions under which these individual forms could be isolated.  
The occurrence of these crystal forms was dependent on two variables, namely β-CD 
concentration in the aqueous mother liquor and the incubation temperature of the solution. 
Careful examination of the sensitive crystallization equilibrium indicated that, at a solution 
 
4 
concentration of 6.52  10-2 M, pure TBCDFLU could be isolated at an incubation 
temperature of 45 C or lower, while pure MBCDFLU crystallized at an incubation 
temperature of 60 C (for both cases the incubation period is over 48 h). MBCDFLU and 
TBCDFLU crystals displayed different stabilities with respect to dehydration when exposed 
to air and hence determination of their respective water contents was performed using 
thermogravimetry on fresh crystals immersed in silicone oil. From a phase solubility study, 
it was established that the association constant for complex formation between -CD and 
fluconazole in solution was very low (27.2 M-1), implying weak host-guest binding. Finally, 
a 1:1 inclusion complex between -CD and fluconazole was isolated and characterized by 
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1.1) CRYSTAL ENGINEERING: AN OVERVIEW 
The discipline of crystal engineering is strictly connected to crystallography and all the 
classical branches of chemistry (analytical, inorganic, organic and physical). Since its 
discovery, various scientists worldwide have been attracted by this young science of the 
solid-state and in the last two decades the interest in the field has grown exponentially. 
Crystal engineering studies the nature of molecular interactions in the context of crystal 
packing and the possibilities of designing new solids with desired physical and chemical 
properties.   
The primary objectives of crystal engineering are crystalline solids, molecular crystals 
representing a subset of these assemblies.  The definition of a molecular crystal was 
proposed for the first time in a book edited by Kitaigorodsky.1 A molecular crystal is a solid 
with molecules packed by intermolecular interactions which may be various in number, 
energy and type. Several types of bonds or attractive interactions are generally present in 
these crystals: hydrogen bonds, halogen bonds (where atoms F, Cl, Br or I are present), 
hydrophobic interactions, -stacking and van der Waals interactions. It is awesome to think 
that there exist many crystals which are packed with interactions whose energy is of the 
order 1-20 kcal mol-1 (a little greater than the thermal energy kT under ambient conditions). 
The first appearance of the term crystal engineering (with the analogous term ‘crystal 
chemistry’) goes back to 1955 and it was disputed between two scientists. Ray Pepinsky 
defined it at a meeting of the American Physical Society2 and Gerhard M. J. Schmidt 
published a paper,3 which referred to a study that commenced in 1950, in which he explained 
the possibility of applying X-ray diffraction to organic chemistry. For this reason, Schmidt 
is widely credited to have introduced the crystal engineering term and to have contributed 
to the birth of organic solid-state chemistry. The first study regarded the solid-state 2+2 
photocycloaddition reaction of trans-cinnamic acids to cyclobutanes. The result showed that 
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the solid-state reactivity in crystals is a characteristic of periodic assemblies of molecules. 
The reactions studied by Schmidt were called topochemical and are reported in Figure 1.1. 
 
 
Figure 1.1: Topochemical photodimerization reactions of different polymorphs of cinnamic acid. It 
is possible to notice the influence of the molecular assembly on the formation of each product.4 
 
In the 1970s the concept of supramolecular chemistry was defined and in 1988, with the 
studies of Ermer on the 3D network of the adamantane-1,3,5,7-tetracarboxylic acid,5 it 
entered the crystal engineering field. This permitted visualisation of an organic crystal 
structure as a proper network (until that time it was considered as a union of assembled 
molecules). A molecular crystal observed with supramolecular analysis is a periodic self-
assembly of billions of molecules held together by non-covalent forces; they are therefore 
supramolecular systems and thus crystal engineering is a form of supramolecular synthesis. 
The fundamental unit of a molecular crystal is the supramolecular synthon.  
 
“Supramolecular synthons are structural units within the supermolecules which can be 
formed and/or assembled by known or conceivable synthetic operations involving 
intermolecular interactions” [G. R. Desiraju].6 
 
A supramolecular synthon is a sub-structural unit in a molecular crystal that can be 
assembled with known synthetic operations. Study of a synthon is fundamental for 
determination or prediction of an experimental crystal structure. In most cases a synthon is 
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composed of common functional groups held together by directional interactions (e. g. O-
H∙∙∙O; C-H∙∙∙O; N-H∙∙∙O; N-H∙∙∙N).  
Crystal engineering is the process by which crystalline materials with specific properties are 
designed and synthesized. Reactivity, tautomerism, change of colour, magnetism and 
solubility represent only a few examples of the properties that depend, chemically or 
physically, on the crystal structure and that are possible to modify. The final use for these 
crystals is as wide as the type of properties modified (e.g. sensors, devices, light sensitive 
materials, catalysts). A recent branch of chemistry, that includes the properties relating to 
polymers and crystal engineering, is the study of metal-organic frameworks (MOFs). The 
MOFs field has a wide range of application due to the possibility of encapsulating liquids 
and gases (these materials have a surface area comparable to, or greater than, those of 
classical zeolites). For industries involved with explosives, dyestuffs and pharmaceuticals, 
the change of solid structure should be fundamental. To obtain different crystalline forms of 
a drug (e.g. solvates, co-crystals or polymorphs) can be of huge commercial interest apart 
from the possibility of altering the pharmacokinetics of an active pharmaceutical ingredient. 
1.2) MULTI-COMPONENT CRYSTALS 
As suggested by the name, a multi-component crystal is a crystalline phase that contains 
more than one type of molecule or ions. The types of interactions and the crystal design 
within a single-component and a multi-component crystal are the same. It is possible to 
expand the meaning of a multi-component crystal into six groups: co-crystals, host-guest 
compounds, mixed crystals (belonging to the widest group of solid solutions), donor-
acceptor complexes (it is worth mentioning the example of the TTF-TCNQ semiconductor 
system),7 solvates and hydrates. The work described in this dissertation has focused on the 
first two groups. 
1.2.1) CO-CRYSTALS  
Co-crystals, according to the FDA definition, are solids that are crystalline single-phase 
materials composed of two or more different molecular and/or ionic compounds generally 
in a stoichiometric ratio.8 It is a very delicate definition and it is necessary to specify that all 
the chemical species involved in the co-crystal must be neutral. In the case of e.g. a proton 
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transfer or the presence of solvent inside the structure, it is necessary to refer to a salt or a 
solvate, respectively.  Solvated co-crystals are not uncommon.  
For co-crystals, the definition of synthon should be divided into two parts based on the types 
of functional groups present (usually they are an acid-base pair). Taking as example a 
carboxylic acid and a primary amide, two types of ring synthons are possible: homosynthons 
(acid-acid and amide-amide) and heterosynthons (acid-amide). In Figure 1.2 are 
represented all the possible ring synthons generated by this pair. 
 
 
Figure 1.2: Schematic representations of typical ring homosynthons and a heterosynthon 
generated by carboxylic acid and a primary amide pair. 
 
Zaworotko was the first to suggest this division and to propose a retrosynthetic approach to 
analyse the structures of co-crystals.9 He observed that the heterosynthons are more 
common than the homosynthons. The reason for this behaviour of molecules should be 
attributed to the robustness of the synthon itself. 
The principles of crystal engineering should be applied to co-crystals intended for a 
pharmaceutical purpose. Drugs are usually sold in solid formulations and for this reason a 
pharmaceutical co-crystal could be useful. These co-crystals should be prepared with an 
active pharmaceutical ingredient (API) and a co-former (COF) selected from the US Food 
and Drug Administration’s “generally recognized as safe” (GRAS) database.10 It is also 
possible that an API might be used as COF but it is necessary to find it in the WHO’s list of 
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essential medicines.11 The Combivir12 case is interesting because it is a commercialized 
example of an anti-HIV co-crystal formed by two different APIs (lamivudine and 
zidovudine). The presence of a COF in a co-crystal of an API can result in physicochemical 
enhancement of the API (e.g. by increasing its solubility, altering its melting point, and 
providing a phase that is less hygroscopic). 
A retrosynthetic13 or a crystallization path should be followed to design a pharmaceutical co-
crystal. Retrosynthesis in crystal engineering is an analysis, analogous to retrosynthesis in 
organic chemistry except that non-covalent bonds are involved in the former while covalent 
bonds are involved in the latter. The crystallization, corresponding to the experimental path, 
is certainly preferable and should be carried out with solution techniques or with 
mechanochemical methods. The crystallization of the product has poor efficiency and needs 
long times but is very useful to determine the crystal structure and investigate the effects of 
different solvents on the crystallization process. Mechanochemical methods are more 
versatile because they permit grinding of solid-solid or solid-liquid systems with or without 
solvents (the experimental efficiency is higher but it is impossible to obtain single crystals). 
The combination of the two methods is advantageous.  
The purpose of pharmaceutical co-crystals is the enhancement of the poor solubility of many 
APIs, whereas previously the primary way to modify the solubility was to convert it into a 
salt. The co-crystal route is also favourable in that APIs and COFs are not necessarily 
required to be acids and bases. Nowadays the co-crystallization approach is a good 
competitor to the old method because, with the improvement of solubility, it leaves the 
component molecules unchanged and potentially enables preparation of solid formulations 
starting from liquid14 or solid APIs without modifying them. 
1.2.2) HOST-GUEST COMPOUNDS: CYCLODEXTRINS  
The term “cyclodextrin” was used for the first time by Franz Schardinger15 in 1911. The 
enzymatic degradation of starch produced the native CDs (illustrated in Figure 1.3) which 
are composed of six, seven or eight D-glucopyranose rings, bonded in α-1,4 linkage (α-, β-, 
γ-CD respectively). The shape of a CD is a truncated cone with two rims called primary and 
secondary (corresponding to the narrower and to the wider sides, respectively). All the CDs 
are soluble in water to different extents: this is due to the presence of a primary hydroxyl 
group on the primary rim and of two secondary hydroxyl groups on the secondary rim per 
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D-glucopyranose unit. The cavities have a lipophilic character. The native CDs can be 
modified to obtain derivatised CDs with different physicochemical properties (such as 
aqueous solubility) that can be used in pharmaceutical applications. The commonest 
modified CDs for industrial appications are: heptakis(2,6-di-O-methyl)--cyclodextrin 
(DIMEB), heptakis(2,3,6-tri-O-methyl)--cyclodextrin (TRIMEB), (2-hydroxypropyl)-β-
cyclodextrin (HPβCD) and (2-hydroxypropyl)-γ-cyclodextrin (HPγCD). 
 
 
Figure 1.3: Schematic representation of native CDs. It is possible to note the presence of the three 
hydroxyl groups per D-glucopyranose unit. 
 
The lipophilic molecular cavity, in a pure CD crystal or in an aqueous solution of pure CD, 
contains water molecules with a high level of enthalpy. If a lipophilic substance is dissolved 
in the aqueous CD solution, it can enter into the CD cavity, expelling included water 
molecules and thus reducing the enthalpy while forming a host-guest complex. Cyclodextrin 
inclusion complexation is a common method employed to modify the physicochemical 
properties of substances with the principles of crystal engineering explained above.   
The CDs have a variable toxicity. A study conducted on rats has shown that β-CD is 
metabolised by the intestinal flora16 and does not generate mutations or diseases if the dose 
is sufficiently low. The types of CDs reported above could be arranged in a general sequence 
(from the least toxic to the most toxic molecule): HPγCD<γ-CD<α-CD<HPβCD<β-CD. This 
sequence was adapted from a paper17 in which the effects of native and derivatised CDs were 
intensively studied on rat and human bodies. CDs have an extremely wide field of 
application: food, cosmetics, toiletry, pharmaceutical, agricultural and tobacco18 industries 
are only a few examples. Despite their toxicity, all CDs reported above are common in these 
 
14 
fields because the toxic poperties are strongly influenced by their solubility (for this reason, 
β-CD, that has a low solubility in water, is widely used in industry). Aroma-containing raw 
materials for foods are stabilised by the action of CDs; the elimination of unpleasant odours 
and the stabilisation of preservatives to improve the qualities of food are often attributed to 
the action of these molecules. Recent studies confirmed an important role of CDs in 
analytical chemistry,19 and in selective complexation20 or purification of solutions 
contaminated by organic pollutants.21 
1.2.2.1) PHARMACEUTICAL APPLICATIONS OF CDs 
The CDs, especially β-CD, are used to make drug formulations for oral and dermal 
preparations. The conversion of liquids into crystalline solids, the enhancement of 
bioavailability and the stabilization of labile compounds are desirable characteristics for the 
pharmaceutical industries. The major part of the β-CD market is consumed by the 
pharmaceutical industry for the production of tablets.  
The advantages for the pharmaceutical industry are similar for some aspects to the 
applications of CDs explained above. More specifically the advantages are: 
 Better drug formulations. Liquid APIs may be complexed in a crystalline form and 
an eventual bad taste or smell can be eliminated; 
  Improvement of physicochemical stability. It is possible to protect APIs with 
sensitive properties such as evaporation, oxidation by air or decomposition by light; 
 Enhancement of bioavailability. Poorly water-soluble substances usually show 
improved dissolution characteristics if included in a CD complex. 
Not all drugs can be complexed by CDs. Three factors can limit the application of CDs in 
oral formulations: complexability, stoichiometry and required dose of drug. The 
hydrophobicity, the relative size and the geometry of the drug molecule in relation to the 
CD cavity are the most important parameters that control the complexability factor 
(expressed as the stability constant). To be acceptable by the pharmaceutical industry, a CD 
inclusion compound should have a stability constant of 200-10000 (less stable to very 
stable). The stoichiometry of CD-drug complexes is predominantly 1:1, 2:1 and 3:2, while 
other ratios have been reported but they are not common.22 The required dose of drug is 
strictly correlated to stoichiometry which indicates the percentage by mass of drug 
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complexed compared to the total mass of the complex. A complex prepared with a low or a 
high molecular weight drug can encapsulate the same percentage of molecules. The 
difference could be reflected in the effective amount of complex that would be large for the 
first and small for the second case. With this reasoning, it is easy to understand that the  
stoichiometry influences the effective size of tablets due to the same amount of encapsulated 
drug being contained in e.g. hundreds of milligrams or tens of milligrams of complex 
(respectively). For the pharmaceutical industries this is a critical point during the 
formulation process because it is also well known that the CDs, in high dosages, are toxic.  
The CDs are useful drug delivery agents. When drug molecules are encapsulated in CDs they 
can be considered as dispersed in the oligosaccharide matrix. The hydophobic drug enters 
into the CD cavity simply by contact, but the aqueous solution of the two substances  (host 
and guest) needs intensive stirring (times vary depending on each case). As explained above, 
CDs are metabolized in the intestine but they are not absorbed in the gastrointestinal tract.23 
A study has revealed that only the 2-4% of CDs are degraded to simple sugars by α-amalyses, 
then they are absorbed by gastro-intestinal membranes (an intact CD molecule would be 
too large to do this).24, 25 The cyclodextrins are only carrier agents, they transport a 
hydrophobic guest molecule through an aqueous medium to the lipophilic membrane 




The criteria for the selection of the studied bioactive compounds, the aims and objectives of 
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The materials used in this study are listed below with their sources.   
The Active Pharmaceutical Ingredients (APIs), which consisted of sulfasalazine 
(C18H14N4O5S) and fluconazole (C13H12F2N6O), were purchased from Sigma-Aldrich Chemie 
Gmbh (Steinheim, Germany). An extensive description of these compounds is reported in 
Chapter 3. 
Native cyclodextrins such as -cyclodextrin (-CD; C36H60O30) and -cyclodextrin (-CD; 
C48H80O40), were purchased from Wacker, Biosolutions (Halle, Germany). -cyclodextrin 
(-CD; C42H70O35), heptakis(2,6-di-O-methyl)--cyclodextrin (DIMEB; C56H96O35) and 
heptakis(2,3,6-tri-O-methyl)--cyclodextrin (TRIMEB; C63H112O35) were purchased from 
Cyclolab Ltd. (Budapest, Hungary). 
Solvents employed in the study were purchased from Sigma-Aldrich (South Africa). 
All materials were used without further purification. 
2.1) CO-CRYSTAL SCREENING 
The co-crystal screening with the drugs was conducted following a precise and systematic 
procedure. At first, co-formers were selected in order to have the potential to build a well-
defined supramolecular synthon with the drug molecule. This study was carried out with the 
use of the Cambridge Structural Database (CSD)1 and ConQuest software was the principal 
program used for this preliminary part of the study. All the co-formers (COFs) used to 
conduct the experimental attempts appeared in the US Food and Drug Administration’s 
“generally recognized as safe” (GRAS) database2 or were reported in the World Health 
Organization’s (WHO’s) List of Essential Medicines.3 
After the theoretical study, each co-former was analysed with a powder diffractometer 
instrument to determine the PXRD pattern of the substance. This expedient is important to 
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identify the polymorphic form found in the bottle of the chemical substance. The first 
process to be employed for co-crystallization was co-grinding. All possible binary 
combinations of drugs and co-formers were co-ground for 10-15 minutes with a mortar and 
pestle. Two techniques were carried out: neat grinding (i.e. without solvent present) and 
liquid-assisted grinding (LAG). For both methods, a small quantity of drug (1-5 mg) and an 
equimolar amount of co-former were added to the mortar. The LAG experiments involved 
the addition of small drops of an appropriate organic solvent that formed with the reactants 
a soft paste in the mortar. Usually, for each API-COF pair three LAGs with different solvents 
and a neat grinding were carried out. 
All the products of grinding were analysed using PXRD. The traces were compared with 
those of the components to try to identify new solid phases. If the co-crystallization do not 
occur the PXRD trace of the product was the sum of the two PXRD traces of the components 
(it was therefore unequivocally identified as a physical mixture). Compared to the 
component traces, if the PXRD pattern of a product of co-grinding displayed new peaks in 
different positions, it was possible to confirm the presence of a new crystal phase. 
Where PXRD indicated the formation of a new phase, co-precipitation experiments were 
performed. Stoichiometric amounts of drug and co-former were dissolved in an appropriate 
solvent; the resulting suspension was then heated to enhance the solubilization process. The 
solution was filtered through a 0.45 μm nylon filter into a clean, pre-heated vial. Vials were 
left in the fume-hood to allow the solvent to evaporate at room temperature. If suitable 
crystals were formed, they were fully characterized using single crystal X-ray diffraction and 
the techniques explained in the paragraphs which follow. 
In the case of failure of co-precipitation experiments, different co-crystallization attempts 




Figure 2.1: Schematic representation of four co-precipitation techniques used to provide single 
crystals for SCXRD analysis: evaporation of a single solvent [1]; evaporation of a multi-solvent 
system [2]; liquid-liquid diffusion or slow interface diffusion [3]; vapour-liquid diffusion [4]. 
 
The schematic representation of the evaporation of a single solvent [1] shows the typical co-
precipitation experiment (explained above); this may be used to explain the seeding 
technique, as follows. After the dissolution of drug and co-former in the hot solvent, the 
solution was slowly cooled and a crystal of the desired product (from a previous synthesis) 
was added to the vial to facilitate the crystallization. The co-precipitation via evaporation of 
a multi-solvent system [2] involves two or more miscible solvents with different volatilities. 
The compounds might be more soluble in the most volatile solvent and, after the evaporation 
of this one, crystals could be formed in the solution of the less volatile solvent. In a liquid-
liquid diffusion [3] the raw materials are dissolved in an appropriate solvent and a second 
one is carefully added on the top to form an interface. It is possible to use this technique with 
different approaches, such as using a pair of miscible solvents with different densities or 
completely immiscible solvents (both were used in this study under different thermal 
conditions). Finally, the vapour-liquid diffusion [4] takes advantage of the same principle as 
that for liquid-liquid diffusion. In this case the solvents might be completely miscible and 





2.2) CYCLODEXTRINS OVERVIEW 
The cyclodextrins (CDs) are oligomeric forms of glucose. The native ones are composed of 
six, seven or eight units of D-glucopyranose rings, linked in the positions α-1,4. The number 
of units determines the name of the molecule: six units correspond to an α-cyclodextrin, 
seven to a β- and eight to a γ-. The truncated conical geometry and the dimensions of each 
cage are shown in Figure 2.2. These data were determinant for a screening with the 




Figure 2.2: Conical morphology and dimensions of the cavities of the native cyclodextrins. 
 
Due to the truncated conical shape, it is possible to identify the presence of two rims: 
primary and secondary. Three hydroxyl groups are present per glucose unit: a primary 
hydroxyl group is located on the narrower (‘primary’) rim in the position labelled as 6 and 
two secondary hydroxyl groups are located on the wider (‘secondary’) rim in the 2 and 3 
positions. In Figure 2.3 is shown the schematic representation of a β-CD molecule and a D-
glucopyranose unit.   
The native cyclodextrins have quite a high content of water inside their structure and their 





Figure 2.3: Schematic representation of the truncated conical shape of a native cyclodextrin (left) 
and of a D-glucopyranose unit (right). On the right side are reported the typical labels for the 
glucoside ring and it is possible to distinguish the positions of the primary and secondary hydroxyl 
groups in the molecule. 
 
Table 2.1: Aqueous solubility of the native cyclodextrins.4 





The low aqueous solubility of β-cyclodextrin is probably related to the strong binding of the 
CD molecules in a network of O-H∙∙∙O hydrogen bonds. These interactions are principally 
intramolecular (forming ‘belts’ that maintain the round shape of the CD). If the CD hydroxyl 
groups are substituted by methoxy groups this physicochemical property changes radically 
(as shown in Chapter 7).  
2.2.1) MOLECULAR GEOMETRY 
The schematic representation of β-cyclodextrin in Figure 2.4 shows the parameters useful 
for describing the modification of its macrocyclic conformation when a guest is present 
inside the cavity. The geometric parameters are six in number and all are based on the seven 
O4 glycosidic oxygen atoms taken as a reference plane. For the case of β-CD (and its 
derivatives), the geometrical figure inscribed in the macrocyclic ring is a heptagon. With this 
figure, it is possible to define all the geometrical parameters: the distance between each O4 
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atom and the centroid of the O4-heptagon (l), the O4O4′ distance (D), the O4O4′O4′′ 
angle (φ) and the O4O4′O4′′O4′′′ torsion angle (d). There are three more parameters 
that are not directly connected to the O4 mean plane. If intramolecular hydrogen bonding is 
present, it is important to cite the O2∙∙∙O3′ distance (D3). The (α) parameter measures the 
deviation of each O4 atom from the O4 mean plane. It is well known that the CDs have a 
truncated conical shape. The last parameter (τ1) is related to the deviation of the conical 
(more accurately ‘toroidal’) shape of the CD molecule from a hypothetical cylindrical shape. 
Generally, it is observed that the primary rim of each individual glucose residue is tilted by 
a characteristic angle τ1 towards the seven-fold axis of the macrocycle. Therefore τ1 = 90° - 








Figure 2.5: (a) O4 mean plane calculated for a β-CD molecule, (b) θ angle between O4 and (C1, C2, 
C3, C4, C5, O5) mean planes used to calculate parameter τ1. The yellow dots indicate the atoms 
used to calculate the planes.   
2.2.2) CRYSTAL PACKING ARRANGEMENTS 
The packing arrangements for a generic cyclodextrin complex could be monomeric or 
dimeric with a channel or cage type (Figure 2.6). The channel type packing has the cavities 
of cyclodextrins aligned and it is possible to distinguish a monomeric arrangement if the 
primary and the secondary rim are in contact; this arrangement is called head-to-tail 
(AAAA). If the channels are formed by head-to-head channels, the structure is dimeric 
(ABAB) and two primary (or secondary) rims are in contact.  The most common cage type 
packing is monomeric and it occurs when the cavities are obstructed. These arrangements 




Figure 2.6: Packing arrangements for cyclodextrin complexes. 
 
The similarity between types of crystal packing arrangements raises the need to explain the 
term ‘isostructurality’. Two or more phases (e.g. from a cyclodextrin complexing different 
guests) that have the same gross packing arrangements or molecular arrangements, as well 
as a common space group and similar unit cell dimensions, are referred to as isostructural 
phases.5 A review by Caira described various isostructural series of PXRD traces for known 
CD complexes and reported that the PXRD patterns were comparable for CD complexes 
within any given series.6 It is now possible to compare the PXRD pattern (or the unit cell 
parameters from a single crystal) of the crystalline product of a CD inclusion experiment and 
determine whether complexation has occurred or not.  
2.3) CYCLODEXTRIN INCLUSION COMPLEX SCREENING   
The cyclodextrin rims are hydrophilic and the cavities lipophilic. A lipophilic molecule 
(guest) can be complexed by a cyclodextrin (host) in solution with the formation of a precise 
equilibrium. The equilibrium constant KC is defined in equation (1) in Figure 2.7, which also 
presents a graphical representation of the formation of a 1:1 complex.7 
𝐾 =  
[ ∙ ]
[ ][ ]
             (1) 
To prepare each inclusion complex, both kneading and co-precipitation experimental 
attempts were carried out with a 1:1 molar ratio of host and guest. The kneading technique 
is very similar to LAG but it uses water instead of organic solvents. For a kneading attempt, 
the raw materials were mixed in a mortar and gently kneaded with a pestle for ~15 minutes, 
the mixture being kept moist with the addition of ~20-25 μl of pure water. The products 
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were analysed using PXRD and each pattern was compared with the calculated traces from 
the isostructural series and with the experimental traces of components. If the powder 
pattern was different from those of the components and matched one of the patterns of the 
isostructural series ones, it was identified as a new complex.  
 
 
Figure 2.7: Reversible complexation of a guest by a CD in solution. 
 
The co-precipitation experiments took place in different modalities. Each cyclodextrin used 
for this study presented different properties. For this reason, each experimental procedure 
will be reported in a separate paragraph at the beginning of the chapters that deal with the 
study of different CD complexes (Par. 5.1, Par. 6.1 and Par. 7.2.1). 
2.4) THERMAL ANALYSIS 
All the thermal analyses described in this paragraph were combined to study the thermal 
behaviour of a new crystal phase or to determine the properties of the drugs. The techniques 
used were Hot Stage Microscopy (HSM), Thermogravimetric Analysis (TGA) and 
Differential Scanning Calorimetry (DSC). To determine the conditions for reliable TGA 
estimation of crystal water content, an empirical test involving timing of the rate of 
dehydration of the crystal was devised. This test was carried out with HSM instrumentation 




Hot Stage Microscopy (HSM) was used as a preliminary test to evaluate the behaviour of a 
crystal with elevated temperatures. Bubbling, colour changes or change of opacity of crystals 
indicates a thermal event that may be correlated to TGA or DSC traces. Samples were placed 
on a cover slip with a small drop of silicone oil and monitored using a Nikon SMZ-10 
stereoscopic microscope fitted with a Linkam THMS600 hot stage and a Linkam TP92 
temperature control unit. The images were captured with a real-time Sony Digital Hyper 
HAD colour video camera and viewed using analySIS (the Soft Imaging System program).8 
2.4.2) DEHYDRATION TIMED TEST 
The Dehydration Timed Test (DTT) was an experiment that was carried out to promote the 
success of thermogravimetric analysis (TGA). Some new crystal phases in this study lost 
water within a few seconds once removed from their mother liquor. The preparation of a 
TGA experiment needed around two minutes. If the sample lost mass during this period it 
would be very difficult to have a good set of data for thermogravimetric analysis. To estimate 
an average time in which the sample lost the solvent contained inside the structure, a single 
crystal was placed on a slide in a small pool of mother liquor. The sample was monitored 
with the HSM instrumentation, without heating the system. After a few minutes, the drop of 
mother liquor had evaporated and the time test began. The images recorded were useful to 
understand the stability of the crystal on exposure to the open air (time of formation and 
position of cracks were the prominent empirical behaviours observed). Certainly, important 
crystal characteristics like shape or thickness could influence the time of formation of cracks, 
but these aspects were not considered due to the difficulty of analysing them in a statistical 
sense. 
2.4.3) TGA AND DSC 
Thermogravimetric analysis (TGA) exposes a solid sample to elevated temperatures. The 
instrument measures the change in mass of sample as a function of temperature. This 
analysis is important and it was used extensively during this study in order to quantify the 
solvent present in crystals. Differential scanning calorimetry (DSC) measures the difference 
in energy as a function of temperature between a sample pan and a reference pan. During 
 
28 
the analysis it is possible to observe both endothermic and exothermic peaks that are directly 
correlated to solvent loss, melting, phase transitions or decomposition. 
A TA-Q500 Thermogravimetric Analyzer with Universal Analysis software (v4.5A, TA 
Instruments-Waters LLC) was used. It was operated with a dry nitrogen purge gas flow rate 
of 60 cm3 min-1 and samples were heated at a rate of 10 K min-1. The samples, in a mass 
range of 1-5 mg, were removed from their mother liquor, dried on filter paper and placed in 
an open crucible. For some samples, due to their nature (Par. 5.3.3), a secondary procedure 
(recording the time for each attempt) was necessary. A small quantity of sample was 
removed from mother liquor, dried on filter paper and placed inside a tared open crucible. 
After a second weighing, 1-2 drops of silicone oil were placed inside the crucible and it was 
weighed a third time.  
Differential scanning calorimetry (DSC) was performed on a DSC25 Differential Scanning 
Calorimeter (TA instruments) with TRIOS software (v4.1.0.3179, TA Instruments-Waters 
LLC). It was operated using a dry nitrogen purge gas flow rate of 60 cm3 min-1 and samples 
were heated at a rate of 10-20 K min-1. Samples, with mass range 1.5-3 mg were removed 
from the mother liquor, dried on filter paper and placed inside a closed vented aluminium 
pan.  
2.5) NMR SPECTROSCOPY 
All the crystals analysed were dissolved in deuterated DMSO (DMSO-d6) for recording their 
1H NMR spectra on a Bruker 300 MHz spectrometer. For the CD inclusion complexes, the 
peaks were assigned and integrated to determine the host-guest stoichiometry and, in the 
case of co-crystals, the same integration was done to confirm the stoichiometry. This 
technique was used also to determine the effective drug purity of all the molecules used in 
this study. 
2.6) FTIR SPECTROSCOPY 
Fourier Transform Infrared (FTIR) spectroscopy was used to check if all of the drug 
employed in the attempted synthesis of a CD inclusion complex was complexed. It was 
possible to establish this by comparing the spectrum of the crystal complex with those of the 
 
29 
CD and the drug. In the complex spectrum, the absorption bands of the CD were more 
evident than those of the drug in the case of total complexation due to the larger mass 
fraction of the CD present. The IR spectra were recorded on a Bruker Tensor27 spectrometer 
with an ATR platinum Diamond 1 reflectance accessory for solid samples. 
2.7) POWDER X-RAY DIFFRACTION (PXRD)  
PXRD patterns were recorded to establish if a new crystal phase was obtained following 
attempted synthesis via co-grinding, co-precipitation and kneading experiments. The 
recorded pattern was compared with the patterns of the drug and the appropriate co-former. 
In the case of the presence of cyclodextrins, it was compared also with a library of reference 
patterns for known series of isostructural inclusion complexes.6,9 If the pattern did not 
match any reference pattern, the likelihood of complexation was low, but further 
investigation of the nature of the product would have to follow.  For the co-grinding case, 
the superimposition of the pertinent PXRD patterns was fundamental to evaluate the 
emergence of new peaks or the disappearance of any peaks from the patterns of individual 
components.  
Two powder X-ray diffraction instruments were used for the measurements: a BRUKER D8 
X-ray diffractometer and a HUBER X-ray diffractometer. Both instruments used a CuKα1-
radiation source (λ = 1.54056 Å). With the Bruker instrument, all the samples were placed 
on a zero-background sample holder (rotating at 10 rpm) and scanned over the 2θ-range 4° 
– 40°, with a step size of 0.05 per second. The X-ray generator settings were 30 kV and 40 
mA. The HUBER X-ray diffractometer used a Philips PW1120/00 X-ray generator fitted 
with a Huber long fine-focus tube PW2273/20 and a Huber Guinier Monochromator Series 
611/5 to produce the CuKα-radiation specified above. The PXRD patterns were recorded by 





2.8) SINGLE CRYSTAL X-RAY DIFFRACTION (SCXRD) 
Single crystals of adequate quality, size and optical uniformity were removed from the 
mother liquor and immersed in a small pool of Paratone N oil.10 They were subsequently 
mounted on a nylon cryoloop. 
Two different instruments were used to check the unit cell dimensions or for full intensity 
data-collections. The unit cell dimension checks were performed on a Nonius KappaCCD 
(where CCD refers to the Charge Coupled Device detector) single crystal X-ray 
diffractometer, using graphite-monochromated MoKα radiation (λ = 0.71073 Å) generated 
by a Nonius FR590 generator operated at 50 kV and 20 mA. The preliminary unit cell 
refinement was performed using the DENZO and SCALEPACK11 programs. The data-
collections were recorded on a Bruker KAPPA APEX II DUO single crystal X-ray 
diffractometer using MoKα radiation (λ = 0.71073 Å) generated by a Bruker K780 generator 
operated at 50 kV and 30 mA.12 All the samples were maintained at low temperature during 
the data-collection (usually 173 K and in some cases 100 K) by cooling with a constant flow 
of N2 gas (rate of flow 20 cm3 min-1). The cryostream cooler was an Oxford Cryostream, UK. 
As in the case of the Nonius instrument, the unit cell refinement and data reduction were 
performed with the programs DENZO11 and SAINT.13 The intensity data were automatically 
corrected for Lorentz-polarization effects while absorption corrections were based on the 
multi-scan method using the program SADABS.14 The observed Laue symmetry of the 
diffraction pattern was fundamental in assigning the crystal system. The space group was 
determined from the systematic absences.  
The input file for the structure solution was elaborated using the program XPREP.15 All the 
crystal structures were solved by direct methods using SHELXS-9716 and refined by full-
matrix least-squares using SHELXL-97.16 These programs were implemented with the X-
Seed17 interface (versions 2.0 and 4.0). 
2.8.1) SHELX-97 
The SHELX-9716 software program uses a full-matrix least-squares fitting to minimize the 
sum of the squares of the differences between the observed (Fo2) and calculated (Fc2) 
intensities. The residual index R1 [defined in (2) below] indicates the agreement between the 
lists of observed (Fo) and calculated (Fc) structure factors. A low R1 index (typical range 
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~0.03-0.05 for small molecules) corresponds to a well-refined model. The second residual 
index is wR2 [defined in (3)], which indicates the agreement between Fo2 and Fc2 for the 
refinement against F2. The parameter w, defined in formula (4), refers to the weighting 
scheme and the parameters a and b appearing in (4) were optimised during the refinement 
of each structure.  The quantity P is defined in (5). The parameter S, defined in expression 
(6), is commonly called the “Goodness-of-Fit”. A well-refined structure has S close to 1.0 and 
a n/p ratio close to 10 (where n and p are equal to the number of reflections and the total 
number of parameters, respectively). 
 
R =  




∑ w (F − F )
∑ w (F )
 (3) 
w = [σ (F ) + (aP) + bP]  (4) 
P =








The program PLATON18 was used to calculate intramolecular and intermolecular 
geometrical parameters, with their standard deviations. Images of crystal structures were 
created with POV-Ray19 software available in program Mercury.20 The final crystallographic 
data files for each crystal structure reported in this study can be found in the Appendix. 





Table 2.2: Crystallographic data files available in the Appendix. 
Extension Details 
.hkl Reflection data 
.res SHELX co-ordinate data 
.cif Crystallographic information 
.lis PLATON output 
.fcf Observed and calculated intensities 
.xl SHELX output 
.sup Tabulated supplementary data 
 
To finalise each model obtained by Single Crystal X-ray Diffraction (SCXRD), a PXRD 
pattern was calculated with the program LAZY PULVERIX21. From the comparison of the 
calculated PXRD pattern with an experimental one (based on material obtained via co-
grinding or co-precipitation) it was possible to confirm the correspondence between the 
model and the bulk material. 
2.9) PHASE SOLUBILITY STUDIES 
The calibration curves for the drugs were constructed by preparing a stock solution of known 
concentration and diluting it to have a set of solutions with varying concentrations. The 
drugs studied have very poor aqueous solubility and therefore, to encourage the dissolution 
process, a small amount of ethanol was added to the solutions. All the phase solubility 
studies were performed in a 1% ethanol/water [v/v] medium. To determine the 
concentration of the drug in solution UV-Visible spectroscopy was used. The fundamental 
equation used to quantify the drug present in each solution was the Beer-Lambert law (7). 
The expression below describes the relation between the absorbance (A) and concentration 
(c) of an absorbing species with a constant path length (l) and a molar absorption coefficient 
(ε0). 
             A = ε lc             (7) 
 
The absorbance readings were recorded on a Cintra 20 UV-Visible spectrometer and data 
were processed using the GBC Spectral computer program (v1.70, December 1998). The 
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readings were plotted as a function of the molar concentration of the drug to construct the 
calibration curve. 
For the phase solubility studies, a set of dilutions of a cyclodextrin solution were prepared 
and an excess of the drug was added to each solution (the volume of solution in each vial was 
3 ml). The vials were sealed and stirred (500 rpm) at constant temperature (25.5 ± 1.0 °C) 
for 36 hours. The solutions were filtered through a 0.45 μm nylon filter, diluted 20-fold and 
analysed with the UV-Visible spectrometer. Using the respective calibration curve, the 
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AIM OF THE STUDY, COMPOUNDS                                        
AND EXPERIMENTAL ATTEMPTS 
 
3.1) AIM OF THIS WORK    
The study motivation focused on the change, via supramolecular intervention (co-
crystallization or cyclodextrin inclusion complexation) of two active pharmaceutical 
ingredients (APIs) that are commonly available on the market. Both targets are slightly 
soluble in water and the final purpose was to improve this physicochemical property for 
possible enhancement in drug delivery. In the first place, it was necessary to check by PXRD 
if a new crystal form was identified. In the second place, it was necessary to further 
characterize it with thermal and spectroscopic analysis and, where possible, to determine its 
crystal structure with SCXRD. 
3.2) SULFASALAZINE 
Sulfasalazine (5-[4-(2-pyridylsulfamoyl) phenylazo] salicylic acid; C18H14N4O5S) is a 
powerful anti-inflammatory drug finding application in chronic diseases like rheumatoid 
arthritis,1 Crohn’s disease,2 ulcerative colitis and pancreatic cancer.3 An image of 
sulfasalazine (SSZ) should read in Figure 3.1, it is a powerful API, derivatised by the 5-
aminosalicylic acid with a moderate effect on these problematic diseases. Nowadays, the 
commonest way to administer SSZ is via oral tablets, such as the registered products 
Salazopyrin or Azulfidine. The solubility of SSZ in water at the temperature of 25 °C is 




Figure 3.1: Group of sulfasalazine crystals photographed at the microscope. 
 
The peculiarity of SSZ is the presence of two recognized tautomers5 with different 
crystalline forms. The procedure to obtain them is long and has a low yield: 50 mg of raw 
material solubilized in 10 ml of a first solvent, heated at 50-60 °C (depending on the 
boiling point of the solvent itself) to have the maximum concentration possible and 
stirred overnight. After the complete evaporation of the liquid, a second recrystallization 
must be set up with a different solvent under the same conditions as the first one. It is 
necessary to evaporate the second solvent slowly and, if possible, perform seeding with 
a crystal of the desired tautomer to encourage the crystallization of the entire sample. 
The specific types of tautomers and solvents are explained below (the CCDC refcodes for 
the respective molecular and crystal forms are given in parentheses). 
 Amine (QIJZOY). This tautomeric form exists as a solid-state dimeric structure with 
hydrogen bonds as principal interaction between the molecules of the dimer (Figure 
3.2). The units are bonded only with an offset-𝜋-stacking interaction of the phenyl 
groups. The solvents used to obtain this tautomer (orange crystalline powder) are 
absolute ethanol 98% (EtOH) or 2-butanone (methyl ethyl ketone, MEK). 
Henceforth, this molecule will be designated A-SSZ, to denote the amine group that 
characterizes the tautomer. 
 Imine (QIJZOY01). The solid-state X-ray analysis shows a structure with chains and 
the same type of interactions as found in the amine tautomer (Figure 3.3). The 
relationship of the phenyl groups with an offset stacking is significantly different from 
that in the other tautomer. In the A-SSZ case, all the phenyl rings are stacked in the 
same way, while in this one, successive pairs of chains are inclined at 46.4. The imine 
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tautomer of sulfasalazine (I-SSZ) is a crystalline dark orange powder and it is 













Fluconazole (2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl) propan-2-ol), is an 
antifungal drug in commercial use since 19886 and has high potency against these 
microorganism infections (Figure 3.4). It is enumerated in the List of Essential Medicines 
of the World Health Organization7 and the demand for its use is rising rapidly.  
 
                                             
Figure 3.4: Representations of the fluconazole molecule. 
 
Fluconazole (C13H12F2N6O) is a solid, white, azole API, that is formulated as tablets, creams 
or solutions. The melting point range is 138-140 °C and the solubility in water is very low (< 
0.001 mg/ml8). The most common forms of fluconazole in commerce are tablets like 
Diflucan, Flucamed or Forcan (principally formed with salts of API). The research on co-
crystals that contain this API is very extensive, principally with carboxylic acids as co-
formers.9,10 For this reason, all the work reported in the present study with this target 
molecule is on cyclodextrin inclusion complexes. 
Using solid-state characterization techniques, it is possible to observe the presence of five 
polymorphic anhydrous forms and one hydrate. The raw fluconazole used in this work 
corresponds to an anhydrous form (CCDC refcode IVUQOF02) with orthorhombic 
symmetry (space group Pbca). The principal interaction in this structure is O-HN 
hydrogen bonding between the hydroxyl group and the nitrogen atom of a triazole group. 
Describing the crystal packing is simple due to the formation of chains of molecules along 
the direction shown in Figure 3.5. 
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Figure 3.5: Solid-state representation of IVUQOF02. 
 
3.4) CO-FORMERS FOR SSZ 
The research on the co-crystallization of SSZ was carried out with the intention of eventually 
forming a hydrogen-bonded synthon with a series of co-formers, using first a literature study 
to explore this possibility, then an experimental attempt. All potential co-former compounds 
chosen were biocompatible (enumerated in the GRAS list11 or in the WHO’s List of Essential 
Medicines7). After the period of study and selection, small amounts of co-former and API (in 
a 1:1 molar ratio) were combined with an appropriate technique of crystallization (dry 
grinding, liquid assisted grinding or LAG, kneading, co-precipitation and liquid-liquid 
diffusion). The product of each attempt was analysed with PXRD to distinguish a possible 
new crystalline phase between its components. Only in the case that this analysis confirmed 
a new phase, were other types of analyses performed (primarily thermoanalytical 
techniques). Below, in Table 3.1, is reported the list of all co-formers used. All the substances 









Table 3.1: Co-formers for the attempts to form co-crystals with SSZ. 
Name Formula Description 
Nicotinic acid 
 
Known also as niacin, it is a 
component, with 
nicotinamide, of Vitamin B3.12 
It is classified as one of the 
essential human nutrients. 
Pyrazinecarboxamide 
 
It is a strong antiuricosuric13 
API commonly used against 
tuberculosis,14 and is included 





In the past it was used for the 
treatment of psoriasis; today it 
is used as food additive (an 
acidity regulator), 




Fundamental in biochemistry. 
The annual production for 
industrial applications like 
food and cosmetics is more 




This is classified in the WHO’s 
List of Essential Medicines as 






Naturally present in wine, it is 
used in food preparations and 







Secreted by organisms and 
industrially synthesized, it is 
used mostly for fertilization of 





Essential nutrient for certain 
animals (like humans). It has an 
enormous field of application in 
areas such as medicine, 
chemistry and biology. 
 
3.5) EXPERIMENTAL ATTEMPTS 
In the next sections of this work, the aspects of results will be discussed. In the Tables 3.2 
and 3.3 are reported all the attempts made with the APIs (SSZ and Fluconazole respectively), 
co-formers and cyclodextrins. In these tables, the first column lists labels identifying specific 
experiments. Co-crystallization/inclusion complex formation attempts that yielded possible 
new solid forms have labels in italic type and the respective partner molecules appear in 
italic underscored type in the two succeeding columns.  
 
Table 3.2: Experimental attempts to form co-crystals/CD inclusion complexes with SSZ. 
LABEL API CO-FORMER RATIO CRYSTALLIZATION 
TECHNIQUES 
SOLVENTS 
1 AS I-SSZ* Nicotinic acid 1:1 Neat grinding, LAG 
Acetone, 
Acetonitrile, THF 
2 AS I-SSZ Pyrazinecarboxamide 1:1 Neat grinding, LAG Acetone, 
Acetonitrile, THF 
3 AS I-SSZ Fumaric acid 1:1 Neat grinding, LAG Acetone, 
Acetonitrile, THF 
4 AS I-SSZ Citric acid 1:1 Neat grinding, LAG Acetone, 
Acetonitrile, THF 
5 AS I-SSZ Lidocaine 1:1 
Grinding, LAG, 













6 AS I-SSZ D-Tartaric acid 1:1 Neat grinding, LAG Acetone, 
Acetonitrile, THF 




8 AS I-SSZ L-Ascorbic acid 1:1 Neat grinding, LAG Acetone, 
Acetonitrile, THF 






Citric acid 1:1 Co-precipitation, LAG EtOH, MEK 
11 AS A-SSZ Urea 1:1 Co-precipitation, LAG EtOH, MEK 




13 AS I-SSZ γ-cyclodextrin 1:1 Kneading,                     
Co-precipitation 
H2O 
14 AS A-SSZ γ-cyclodextrin 1:1 Kneading,                     
Co-precipitation 
H2O, EtOH 
15 AS A-SSZ β-cyclodextrin 1:1 Kneading,                     
Co-precipitation 
H2O 
16 AS A-SSZ Nicotinic acid 1:1 LAG EtOH 
17 AS A-SSZ Fumaric acid 1:1 LAG EtOH 
18 AS A-SSZ Pyrazinecarboxamide 1:1 LAG EtOH 
19 AS A-SSZ L-Ascorbic acid 1:1 LAG EtOH 
20 AS A-SSZ D-Tartaric acid 1:1 LAG EtOH 
21 AS I-SSZ α-cyclodextrin 1:1 Kneading,                     
Co-precipitation 
H2O 
22 AS A-SSZ α-cyclodextrin 1:1 Kneading,                     
Co-precipitation 
H2O 
23 AS I-SSZ TRIMEB 1:1 Co-precipitation H2O 
24 AS A-SSZ TRIMEB 1:1 Co-precipitation H2O 
25 AS I-SSZ DIMEB 1:1 Co-precipitation H2O 
26 AS A-SSZ DIMEB 1:1 Co-precipitation H2O 





Table 3.3: Experimental attempts to form CD inclusion complexes with Fluconazole. 




50 AS Fluconazole β-cyclodextrin 1:2 Kneading, Co-precipitation H2O 




52 AS Fluconazole α-cyclodextrin 1:1 Kneading, Co-precipitation H2O 
53 AS Fluconazole TRIMEB 1:1 Co-precipitation H2O 
54 AS Fluconazole DIMEB 1:1 Co-precipitation H2O 
 
The total number of experiments performed was 165.   
If the first LAG or kneading experiment with a particular co-former did not yield a PXRD 
pattern indicating a possible new product (e.g. 18 AS), a new co-former was immediately 
introduced for further experiments. In certain cases (e.g. 5 AS and 12 AS for SSZ, and 50 AS 
and 51 AS for fluconazole), where positive results were identified at an early stage, a large 
number of further experiments followed in order to obtain better definition of the new 
product and to isolate single crystals for X-ray structural studies.  These examples will be 
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STUDIES ON SULFASALAZINE:                                          
CO-CRYSTALLIZATION AND CYCLODEXTRIN 
INCLUSION COMPLEXATION 
 
The differences between functional groups on the two tautomers of sulfasalazine (SSZ) 
(Figure 4.1) are fundamental for the formation of a new crystalline phase. Aminic 
sulfasalazine (A-SSZ) presents a 2-aminopyridine group and imine sulfasalazine (I-SSZ) has 
a 1-hydropyridine-2-imine group. The synthons that each molecule should build with a co-
former are similar but different for this portion of the molecule. The second portion, that 
could already form synthons, is a salicylic acid-diazenide group both in A-SSZ and I-SSZ.  
 
 
Figure 4.1: Schematic representations of A-SSZ (a) and I-SSZ (b). 
 
The difference between each tautomer should be distinguishable also by PXRD analysis. In 




Figure 4.2: PXRD pattern comparison between A-SSZ (blue trace) and I-SSZ (orange trace) to 
underline the difference between the two crystalline structures. A-SSZ trace has been 
mathematically rescaled to facilitate the comparison. 
 
Given these structural differences, it was expected that some co-formers (COFs) and 
cyclodextrins (CDs) could react preferentially with only one tautomer. Table 4.1 shows the 
results obtained for the attempts underscored in Table 3.2 of Chapter 3. 
 
Table 4.1: Experimental results with SSZ tautomers and different co-formers. 
 I-SSZ A-SSZ 
LIDOCAINE New crystalline phase New crystalline phase 
UREA Physical mixture New crystalline phase 
CITRIC ACID Physical mixture New crystalline phase 




For all the positive results reported in Table 4.1, it was impossible to determine the product 
crystalline structures due to the absence of single crystals. It was instead possible to study 
them with other types of analysis such as powder X-ray diffraction (PXRD), thermal 
techniques (HSM, DSC, TGA) and spectroscopy (1H-NMR, IR). 
4.1) SULFASALAZINE CO-CRYSTALLIZATION EXPERIMENTS 
4.1.1) SSZ AND LIDOCAINE (Expts. 5 AS AND 12 AS, Chapter. 3) 
The experiments were carried out in a considerable number for the possibility of obtaining 
a new crystalline phase with two drugs. The lidocaine interacted with both the sulfasalazine 
tautomers but it was not clear how it did so. The physical state was amorphous for all the 
products (28 in total) and it was impossible to determine their formulae or structures. All 
the crystallization techniques were tried: neat grinding, liquid-assisted grinding (LAG), 
vapour diffusion, liquid-liquid diffusion (with miscible and immiscible solvents), co-
precipitation and seeding. The first physical property that changed in the products was the 
colour. A-SSZ and I-SSZ have, respectively, an orange and a dark orange colour, the finely 
powdered lidocaine is colourless and the LAG or ground products were orange-red. This 
evidence, revealed again with more solvents and sometimes with diffusion or co-
precipitation, suggested that a new phase might have formed by combining these 
substances. The problem was the amorphous character, which hampered their 
characterization. All the co-precipitation attempts were carried out in an adapted Pasteur 
pipette, tapered to form a small and long vial. The small surface area of liquid reduced the 
evaporation rate significantly, preventing the formation of the amorphous red paste. The 
results were not encouraging. Figure 4.3 shows the images of the tautomers of sulfasalazine 
and COF powders and the results of grinding processes. The PXRD patterns of the two 
products (Figures 4.4 and 4.5) are very different: the first product, with I-SSZ, was prepared 
by LAG in THF and it is completely amorphous; the second, with A-SSZ, was obtained via 
dry co-grinding and it was the only one product, from the complete set of attempts, that 
presents a crystalline character (albeit low). Figure 4.5 were very useful for understand the 
loss of crystallinity but the traces were not easily comparable. For these reasons, the data of 




Figure 4.3: Difference in the colours of the SSZ tautomers and colour changes which occurred with 
the experimental co-grinding attempts of the individual tautomers with lidocaine. 
 
 
Figure 4.4: PXRD traces of I-SSZ (black), Lidocaine (blue) and the amorphous product of LAG 





Figure 4.5: PXRD confirmation of a new crystalline phase (red trace) obtained from dry co-
grinding of A-SSZ (black trace) and lidocaine (blue trace).  
 
 
Figure 4.5A: Figure 4.5 mathematically rescaled to facilitate the comparison between traces. 
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The importance of the red pattern, in Figure 4.5 and Figure 4.5A, would become very 
significant later. It corresponded to the only product that had presented a low crystalline 
character. The procedure to obtain the amine tautomer in an adequate quantity to proceed 
with the crystallization attempts had a low yield. For this reason, the quantities of A-SSZ 
were always meagre and the author was often forced to use small quantities of powders for 
the attempts. The intention was to prepare other samples shortly after (unfortunately all 
subsequent attempts with the same operating procedure yielded products that were 
completely amorphous).   
4.1.2) A-SSZ AND UREA (Expt. 11 AS, Chapter 3) 
After some grinding studies on both tautomers of SSZ, it was discovered that only the A-SSZ 
interacts with urea. All the compounds used for these experiments are shown in Figure 4.6 
and all samples are fine powders except the one at the bottom right. At a glance, it is possible 
to see the difference of physical state between the two product powders. The LAG, done in 
EtOH, produces a paste if conducted for a long time (~ 15 min) and with vigour. On the 
contrary, if the force used and the duration of LAG (~ 10 min) are both less, the product is 
more crystalline. It is possible to notice the loss of crystallinity in Figure 4.7, where the 
PXRD patterns of A-SSZ, urea and the ground products are reported.   
 
 





Figure 4.7: PXRD pattern of new crystal phase A-SSZ-urea (red) compared with urea (blue) and 
pure A-SSZ (green) PXRD traces. Notice the loss of crystallinity of the A-SSZ-urea pattern 
compared to the pure urea one. 
All the attempts at co-precipitation failed, resulting in separate crystallization of each 
substance in vials.  
4.1.3) A-SSZ AND CITRIC ACID (Expt. 10 AS, Chapter 3) 
For lack of time, the study on this attempt produced only a PXRD confirmation of the 
presence of a new crystal phase (red PXRD trace in Figure 4.8). It was prepared with a LAG 





Figure 4.8: PXRD pattern of the new A-SSZ-citric acid crystal phase (red trace), compared with 
PXRD patterns of pure citric acid (green trace) and A-SSZ (blue trace). The red trace has been 
mathematically rescaled for clarity. 
4.1.4) A COMMENTARY ON PXRD TRACES AND CONCLUSIONS 
It is known that the grinding process can modify the solid-state of the components in the 
mortar. A polymorph1 or a tautomer2 might be generated with a different time of grinding, 
energy or type of solvent. Observing the PXRD patterns relative to the new crystal phases 
(A-SSZ-lidocaine, A-SSZ-urea and A-SSZ-citric acid) of Figures 4.5, 4.5A, 4.7 and 4.8, it was 
possible to notice an isostructural characteristic and a possible similarity with the I-SSZ 
PXRD profile. In Figure 4.9 is reported a PXRD pattern comparison of all new crystal phases 
and the SSZ tautomers. The result is an elevated level of agreement of the three crystal 
phases and the I-SSZ pattern (the reader is reminded that the starting tautomer for these 
attempts was A-SSZ). Therefore A-SSZ, during each LAG experiment, was evidently involved 
in the tautomerization process to become I-SSZ and each co-former changed its physical 
state from crystalline to amorphous. This should be considered uncommon but it is the only 
explanation possible for the result reported below. 
This unexpected effect undermined efforts to achieve the desired reactions. To obtain a 
single crystal, many attempts were carried out with very slow crystallization techniques (low 
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temperatures or evaporation rates of solvents) trying to avoid the formation of the 
amorphous phase observed with the mechanochemical approach. A slow phase diffusion is 
a good example. The experiment was carried out with both SSZ tautomers and lidocaine 
(1:1). The system was left undisturbed in the refrigerator at 4 °C for 3 months but no crystals 
formed at the interphase between immiscible solvents. A large number of other experiments 
were carried out for a total of 68. The formation of a single-crystal was not observed, only 




Figure 4.9: PXRD pattern comparison of A-SSZ-lidocaine (red), A-SSZ-urea (green), A-SSZ-citric 
acid (blue), A-SSZ (black) and I-SSZ (orange). Notice the elevated degree of agreement of each 
product with I-SSZ, evidence for the tautomerization process which had occurred during all the 
LAG experiments. 
4.2) I-SSZ AND γ-CD (Expt. 13 AS, Chapter 3) 
A new crystal phase between I-SSZ and -CD was obtained by means of delicate kneading 
(~15 min) with 25 μl of Milli-Q® water. The powders of host and guest were in a 1:1 
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stoichiometric ratio. Other attempts with the same experimental conditions were carried out 
with A-SSZ as guest without any encouraging result. The appearance of I-SSZ-γ-CD was a 
light orange powder. After the preliminary attempt and the analysis using PXRD (Figure 
4.10), other crystallization techniques were explored.  
 
 
Figure 4.10: PXRD pattern of new crystal phase I-SSZ--CD (red) compared with PXRD traces of 
pure I-SSZ (blue) and -CD (green). 
 
The confirmation of the presence of a new inclusion complex was obtained by showing that 
the red PXRD trace in Figure 4.10 matched the reference PXRD pattern for known -CD 
inclusion complexes reasonably well.3 Using the principle of isostructurality, this implies 
that the structural arrangement of the host -CD molecules in the new inclusion complex is 
known, but the precise location of the guest molecules within the channel created by the 
stacked host molecules is not.    
No co-precipitation or seeding (using a bit of powder as seeds) attempts gave encouraging 
results and no single crystals of the complex were prepared (all vials presented a separate 
crystallization of I-SSZ and γ-CD). For these reasons, all possible analyses (thermal and 
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spectroscopic) were carried out but it was impossible to determine the structure of the 
complex using singe crystal X-ray diffraction. 
The first thermal analysis was HSM. The images below (Figure 4.11) show the best series of 
micrographs from a set of three experiments with this instrument to determine the 
behaviour of the complex with increasing temperature until its degradation.  
 
 
Figure 4.11: HSM on the inclusion complex I-SSZ--CD. 
 
It is important to recall the melting range of I-SSZ (265-266 °C) and the degradation point 
of γ-CD (267 °C). Progressively from 27 °C to 190 °C the complex in powder form became a 
bit darker, which could be a sign of dehydration (in the picture relative to 190 °C, two small 
bubbles are present. No vigorous bubbling was observed but the dehydration phenomenon 
is underscored by TG and DSC analyses that present a signal variation around 100 °C. The 
solvent used to carry out the kneading process was water only; no other solvents were used 
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to prepare this sample. The decomposition began at 240 °C and it was complete at 250 °C. 
The relatively low temperature of degradation, compared with I-SSZ and -CD melting 
points, confirmed the new crystalline phase. The bubbles visible in the last picture (250 °C) 
are caused by the formation of CO2. 
The 1H-NMR spectrum in DMSO-d6 is reported in Figure 4.12. It was used to check if the 
stoichiometric ratio between I-SSZ and γ-CD was different from the one used to prepare the 
sample (host and guest were inserted in the mortar in a 1:1 molar ratio). In Table 4.2 all the 
integration peaks for this analysis are summarized. The data indicate that the stoichiometry 
remained 1:1.  
 
 







Table 4.2: 1H-NMR integration peaks for inclusion complex I-SSZ--CD. 
Proton δ (ppm) Multiplicity J (Hz) Integration 
Experimental/ 
Theoretical 
HH 8.35-8.37 d 2.1 1.00 1.00 
HF, HG, HA, HI, HL 7.94-8.11 m / 6.32 0.90 
HC 7.73-7.80 m / 1.03 1.03 
HE 7.26-7.27 d 6.3 0.96 0.96 
HD 7.14-7.17 d 6.9 1.07 1.07 
HB 6.85-6.90 t 4.8 0.96 0.96 
H8 5.71 s / 14.5 0.91 
H1 4.87-4.95 d 3 9.79 1.22 
H2, H3, H4, H5, H6 3.51-3.69 m / 48.07 1.00 
*reference integral 
Three hydroxyl protons (HM and H7) are absent from the spectrum. This could be explained 
assuming a signal overlap with the broad water peak of the solvent at 3.3 ppm. The peaks at 
2.5 ppm and 3.3 ppm were not analysed because they were referable to the signals of DMSO 
and water, respectively.  
In the Appendix section it is possible to find the 1H-NMR spectra of pure γ-CD and pure I-
SSZ (Figures A1 and A2, respectively). The analysis and the comparison of these results were 
useful to clarify the commentary written above. In Figure A1, the hydroxyl proton H7 was 
present. Therefore, it was possible to conclude that the overlap in Figure 4.12 is a realistic 
hypothesis. The effects of complexation were clear for three more signals: 
 the H8 signal in the complex spectrum, Figure 4.12, it was a broad peak and in Figure 
A1 it was a well resolved peak: 
 the axial protons of γ-CD H2 and H4 are completely overlapped with H3, H5 and H6 
signals in Figure 4.12 while, in Figure A1, it was possible to observe two, separate 
and well resolved, multiplets. 
In Table A2 of the Appendix, it was evident that the HB proton was a multiplet instead of a 
triplet, as reported in Table 4.2. The reason for this alteration is probably related to the low 
concentration of complex inside the NMR tube. 
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To determine the water content of the complex, TG and DSC investigations were performed 
in a set of three attempts per type of analysis. The results were consistent but they did not 
fully confirm the HSM test (vigorous bubbling in the dehydration temperature range 
evidenced by TGA was not observed in HSM). The combined TG and DSC curves are 
reported in Figure 4.13. It was possible to find the average percentage of water lost during 
the TG experiment (13.4% ± 0.1 %) and, with equation (8), the corresponding number of 
water molecules (n=15 ± 0.3) has been calculated. It was thus possible to state the full 
stoichiometric chemical formula of the 1:1 complex, namely C48H80O40C18H14O5N4S∙15H2O. 
 
% =  
 × 
    (  × )
          (8) 
 
 
Figure 4.13: Overlaying of TGA (blue trace) and DSC (green trace) for the I-SSZ--CD inclusion 
complex. 
 
To conclude, it is possible to state that only the I-SSZ tautomer could interact with the host 
to form an inclusion complex. Some experimental attempts to form a complex between γ-
CD and the tautomer A-SSZ were carried out and the results were all negative. This result is 
consistent with an earlier study in which it was reported that only the imide tautomer of SSZ 
 
61 
formed inclusion complexes with both - and -CD via kneading, while neither of the two 
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β-CYCLODEXTRIN INCLUSION OF FLUCONAZOLE:    
TWO NOVEL FORMS OF AN ANTIFUNGAL DRUG. 
 
Fluconazole, as anticipated in Chapter 3, is an antifungal drug of wide use in pharmacy. Its 
low solubility in water (~1 mg/l at 25 C)1 could be improved via complexation with 
cyclodextrins, as explained in the introductory chapters. 
5.1) EXPERIMENTAL  
With an accurate procedure explained below, two forms of an inclusion complex between 
fluconazole and -CD (Figure 5.1) were isolated: the first crystallizes in a monoclinic space 
group (MBCDFLU) and the second crystallizes in a triclinic space group (TBCDFLU). The 
aspects related to their structural analyses by X-ray diffraction will be explained later.  
                             
Figure 5.1: Schematic representations of fluconazole (left) and of β-cyclodextrin (right). 
 
A concentrated solution of β-cyclodextrin was prepared by adding ~37 mg (0.1208 mmol) 
to 0.5 ml of pure water. Keeping the solution stirred, the temperature was raised to 60 °C. 
The fluconazole was added slowly into the vial (~1 mg every hour for a total of ~5 mg) and 
then the solution was stirred for a period of 20-24 h, keeping the temperature constant. The 
solution was then filtered through a 0.45 m filter into a clean, pre-heated vial. A Dewar 
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flask was filled with hot water and the vial was immersed in the flask. The system was 
covered with tinfoil and hydrophilic cotton to isolate it from the surroundings and it was left 
to incubate, followed by slow cooling for two days. Large, colourless crystals were obtained.  
The temperature of incubation was critical to differentiate the crystal forms. If the process 
started at 60 °C the only form obtained was the monoclinic one, whereas if it started at 45 
°C or less, only the triclinic form was obtained. Together with the incubation temperature, 
the concentration of the solution of β-cyclodextrin was the second variable for the formation 
of these crystals. In an attempt without incubation, with slow evaporation and low 
concentration of β-cyclodextrin (2.95  10-3 M), the result was a mixture of triclinic and 
monoclinic forms. The difference between them is their degree of hydration, and thus they 
are not polymorphs. 
In Table 5.1 are reported two sets of incubation data with different concentrations and the 
types of forms obtained (M = monoclinic, T = triclinic). To determine which type of complex 
had crystallized inside each vial, three crystals were casually selected from each batch and 
their unit cells were determined by single crystal XRD. To ensure homogeneity of crystal 
form, all the remaining crystals were subsequently analysed by PXRD.  
 
Table 5.1: Experimental conditions for the preparation of TBCDFLU and MBCDFLU.  








Incubation T. Crystals Type of 
form 
50-4 AS 0.5 5 37 6.52  10- 2 60 °C √ M 
 
 
SET No. 1 
 
 
0.5 4 29.6 5.21  10- 2 60 °C √ M + T 
0.5 3 22.2 3.91  10- 2 60 °C √ M + T 
0.5 2 14.8 2.61  10-2 60 °C √ M + T 
0.5 1 7.4 1.3  10-2 60 °C √ T 
0.5 0.5 3.7 6.52  10-3 60 °C × × 






0.5 4 29.6 5.21  10- 2 45 °C √ M + T 
0.5 3 22.2 3.91  10- 2 45 °C √ T 
0.5 2 14.8 2.61  10-2 45 °C √ T 
0.5 1 7.4 1.3  10-2 45 °C √ T 





The inclusion complex can be prepared also via kneading. The same amounts of raw 
materials used for the co-precipitation attempts were mixed in a mortar and kneaded for 
~15 minutes with ~20 μl of pure water. The powder obtained (called 50-1 AS) was analysed 
by PXRD. The pattern of 50-1 AS is reported in Figure 5.2 and it is compared with the PXRD 
traces of pure host and guest. It was used only to check the presence of an inclusion complex.  
 
 
Figure 5.2: Powder pattern of 50-1 AS kneaded (red) compared with those of β-CD (blue) and 
fluconazole (green). 
 
The 50-1 AS powder was recrystallized with an incubation at 60 C and analysed again by 
PXRD. A subsequent analysis on this aspect was carried out after the completion of the 
study. The PXRD patterns of 50-1 AS before and after the recrystallization were compared 
with the two calculated patterns of TBCDFLU and MBCDFLU (Figure 5.3) based on their 
single crystal XRD structures (described later). The kneading process, that excludes the 
incubation procedure, leads to the complexation of raw materials in the triclinic form. If the 
powder is recrystallized by the incubation procedure, a form can be preferentially obtained 





Figure 5.3: Comparison of 50-1 AS kneaded (red) and recrystallized (yellow) powder patterns. In 
the middle of the figure are reported, as references, the calculated PXRD traces of MBCDFLU (blue) 
and TBCDFLU (green).  
 
It is possible to conclude that the preferred way to produce the monoclinic form is via the 
co-precipitation method that involves the incubation at the temperature of 60 °C. It is also 
possible to confirm that both forms could be prepared by a simple recrystallization, paying 
due attention to the concentration and temperature of the solution. 
5.2) NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
Only a single 1H-NMR spectrum is reported here (namely that for MBCDFLU) because both 
MBCDFLU and TBCDFLU have the same host-guest stoichiometry and the only expected 
change visible with nuclear magnetic resonance spectroscopy would be a different peak for 
water. The MBCDFLU spectrum is reported in Figure 5.4 and in Table 5.2 the relative 
integrations of peaks are presented. The underlined peaks in the spectrum (green) are those 





Figure 5.4: 1H-NMR spectrum of MBCDFLU in DMSO-d6.  
 
Table 5.2: 1H-NMR integration peaks for MBCDFLU. 
Proton δ (ppm) Multiplicity J (Hz) Integration 
Experimental/ 
Theoretical 
HE 8.31-8.32 s / 2.00* 1.00 
HF 7.79 s / 1.70 0.85 
HB 7.12-7.24 m / 1.87 0.96 
HA 6.84-6.92 d of t 1.8, 6 0.65 0.65 
HD 6.32-6.33 s / 0.96 0.96 
H8 5.58-5.74 d x 2 5.1, 1.8 38.83 1.39 
H1 4.79-4.87 d 2.7 18.88 1.34 
HC 4.50-4.78 q 12, 54 6.27 1.56 
H7 4.35-4.46 t 3 19.73 1.41 
H3, H5, H6  3.60-3.73 m / 55.19 0.99 
H4 3.51-3.60 d 9 23.44 1.67 




Crystals of both forms were dissolved in DMSO-d6. After the integration, the results 
confirmed the ratio β-CD:fluconazole of 2:1. The protons used to define the ratio were H1 for 
the cyclodextrin and HE for the fluconazole. The signals of all protons of the cyclodextrin 
suffer overlap and it was thus impossible to establish a perfect integration in every case. 
5.3) THERMAL ANALYSIS 
To evaluate the differences and the similarities between MBCDFLU and TBCDFLU, their 
thermal analyses are reported together. They were carried out using Hot Stage Microscopy 
(HSM), Thermogravimetric Analysis (TGA), Differential Scanning Calorimetry (DSC) and 
an empirical test called herein Dehydration Timed Test (DTT). The last analysis was set up 
specifically to evaluate the loss of solvent as a function of time for both forms and facilitate 
the consistency of thermogravimetric analysis. 
5.3.1) HSM 
Crystal samples were removed from the vials and rapidly immersed in a small drop of 
silicone oil. The two forms had a similar stability at elevated temperatures. MBCDFLU 
cracks due to water loss at 54°C and TBCDFLU at 50°C. These complexes have a somewhat 
different degradation point that could be seen at 308°C for MBCDFLU and at 320°C for 
TBCDFLU. Both experiments, reported in Figures 5.5 and 5.6, were recorded at a heating 














Figures 5.5 and 5.6: HSM of MBCDFLU (left column) and TBCDFLU (right column). 
 
5.3.2) DEHYDRATION TIMED TESTS 
After the HSM study, both forms were analysed by thermogravimetry. The results were very 
different for samples taken from the same vial and having similar masses. It was necessary 
to do a preliminary test to evaluate the time of dehydration of both forms without the silicone 
oil used for subsequent HSM experiments.  
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Two crystals (Figure 5.7, triclinic, at the top, and monoclinic, below it) were placed on a 
microscope slide in their mother liquor and allowed to dry spontaneously in order to 
determine, qualitatively, the stability of the forms with respect to dehydration. The first 
image (0 seconds) corresponds to the instant at which the mother liquor has evaporated 
completely.  
           
                       0 s                                              12 s                                             18 s 
        
                                                85 s                                              165 s 
Figure 5.7: Dehydration of MBCDFLU and TBCDFLU. 
 
After 12 seconds, MBCDFLU had developed cracks due to its dehydration. The cracks 
became very visible after six more seconds (18 s). With this empirical test, it was possible to 
conclude that MBCDFLU is more unstable when exposed to the atmosphere than TBCDFLU. 
5.3.3) THERMOGRAVIMETRY ANALYSIS WITH SILICONE OIL 
This type of analysis is fundamental to estimate the content of water inside the crystals and 
to eventually correlate the results with the respective crystallographic models obtained by 
single crystal X-ray diffraction (section 5.5). 
The operational times for preparing a sample for a TG analysis had an average of 1-2 
minutes. Due to the rapid dehydration of MBCDFLU, this operational time was too long to 
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obtain a consistent set of data for the mass loss. This instability on exposure to the 
atmosphere was related primarily to the location of the water molecules in the crystals.  
Other potential causes could also contribute to instability but assessment of these would 
require an advanced computational approach to take in account e.g. the morphology and 
surface features of the crystals. The latter could change the total area in contact with the air 
and for a macroscopic system this would yield erroneous measurements because some 
crystals should dehydrate earlier or later proportionally to the surface area. The shape of the 
crystals is a secondary source of error because, taking as an example a MBCDFLU crystal, it 
is easy to understand that a thin crystal would lose water faster than a thick crystal. The first 
set of analyses showed a very wide range of results, namely a mass loss ranging from 8% to 
25%. In order to avoid the problems related to the variable water loss of MBCDFLU, all the 
thermogravimetric experiments were conducted with the crystals in silicone oil. TBCDFLU 
was treated in same way for consistency between data. The software of the instrument was 
programmed for a small sample (~5 mg) which, with the oil added gave a total mass of ~40 
mg. The instrumental error was larger but this was the only way to try to ensure reproducible 
results. 
Each clean platinum crucible used for analysis was calibrated with both TG instrument and 
a laboratory scale. After this check, the samples were removed from the mother liquor, dried 
quickly on filter paper and placed inside the crucible. The weight was recorded quickly and 
the crystals were covered with 1-2 drops of silicone oil. The weight data was recorded again, 
the crucible was inserted into the TG instrument and the analysis was started. The procedure 
was repeated for all experiments (30 in total) and the average time for these operations was 
52 seconds. A run without crystals was carried out in order to study the behaviour of silicone 
oil under the applied temperature program. This experiment was carried out but not 
recorded because the oil was inert (only instrumental variations of the profile were present). 
Figure 5.8 presents the most consistent data in a set of fifteen analyses performed on 




Figure 5.8: TG curves for MBCDFLU. 
 
The formula (9) shows the operational method used to calculate the average number (n) of 
water molecules per complex unit inside the crystal. For the host-guest stoichiometric ratio 
2:1, 𝑛 = 28.4 ± 2.8. 
These thermogravimetric analyses were very consistent because they limited the 
uncontrolled crystal water loss, minimising the experimental error. The only problematic 
points were the increase in the instrumental error and the necessity for calculating the 
curves to remove quantitatively the effects of the oil on the sample. This was carried out with 
a simple subtraction through Microsoft Excel. The data collected before each TG experiment 
were useful to establish exactly the amount of silicone oil present in the crucible. The 
calculated data were used to revise the curves obtained by the TG experiments with oil. In 
these raw profiles, the total mass was composed of crystals and oil. The oil mass values were 
mathematically removed from each point of the curves with the aim of obtaining the profile 





Figure 5.9: TG curves for TBCDFLU. 
 
Using the same formula (9), the number (n) of water molecules per 2:1 host-guest unit of 
TBCDFLU was calculated. The percentage mass loss was 15.3 ± 0.8 % and n = 25.8 ± 1.1. 
 
% 𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 =  
𝑛 ×  𝑀𝑊
2 × 𝑀𝑊  + 𝑀𝑊 + (𝑛 ×  𝑀𝑊 )
   ×  100         (9) 
 
5.3.4) DIFFERENTIAL SCANNING CALORIMETRY 
To facilitate reading, in this chapter, TG and DSC curves were separated. In Figure 5.10 and 
5.11 are reported the DSC traces for MBCDFLU and TBCDFLU, respectively. No oil was 





Figure 5.10: DSC curve of MBCDFLU. 
 
 
Figure 5.11: DSC curve of TBCDFLU. 
 
The two profiles are different for the dehydration peaks: both are present but the MBCDFLU 
peak is sharper than that for TBCDFLU. This difference is due to the different structures of 
the crystals (as reported in the paragraphs describing the crystal structures in Chapters 5.5 
and 5.6; the MBCDFLU channel crystal packing can explain the rapid dehydration, whereas 
the TBCDFLU dehydration is instead slower due to a brick-cage crystal packing). Between 
200 °C and 400 °C the curves are identical (the decomposition peak is at 325 °C).  
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5.4) FOURIER TRANSFORM INFRARED SPECTROSCOPY 
The FT-IR spectrum was recorded with an ATR instrument only on the MBCDFLU complex. 
The peak at 1023 cm-1 is characteristic of the glycosidic C-O bonds in the cyclodextrin, while 
the triazole groups of fluconazole are responsible for the peak at 1625 cm-1 and the broad 
peak at 2960-3760 cm-1 (O-H) is due to the presence of a large quantity of water within the 
complex crystal. The spectrum of TBCDFLU was not recorded. 
 
 
Figure 5.12: IR spectrum of MBCDFLU. 
5.5) SOLID-STATE X-RAY ANALYSIS OF MBCDFLU 
5.5.1) DATA-COLLECTION AND SPACE GROUP DETERMINATION 
The intensity data-collection for MBCDFLU was recorded in a previous study2 (at the 
temperature of 173 K). The dimeric host structure was well-resolved but it was impossible to 
determine the structure and precise location of the guest molecule due to the presence of 
only weak difference Fourier peaks within the host cavity. During the present study, a data-
collection using a freshly-prepared crystal of MBCDFLU was performed at the temperature 
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of 100 K. The higher-quality data obtained at the low temperature were determinant in 
resolving the structure completely by revealing the guest molecule inside the cavity of the 
host. 
The reflection intensities were collected with a Bruker KAPPA APEX II DUO single crystal 
X-ray diffractometer using MoK-radiation ( = 0.71073 Å). After the integration of the 
frames with the Bruker SAINT3 software, absorption corrections based on the multi-scan 
method were applied using the SADABS4 software. The crystal system, confirmed by the 
program XPREP5 was found to be monoclinic (from Laue symmetry 2/m) and the space 
group was identified as C2 from the conditions limiting possible reflections [hkl: h + k = 2n; 
h0l: (h = 2n); 0k0 (k = 2n)], the alternative space groups Cm and C2/m being eliminated 
since the host is chiral. Crystal data and structural refinement results are shown in Table 
5.3.  
 
Table 5.3: Data-collection and refinement parameters for MBCDFLU. 
Abbreviated formula 2 β-CD ∙ FLUCONAZOLE ∙ 21.28 H2O 
Complex formula (C42H70O35)2 ∙ C13H12ON6F2 ∙ 21.28 H2O 
Formula weight (g mol-1) 2908.49 
Data-collection temperature (K) 100(2) 
Crystal system monoclinic 
Space group C2 
a (Å) 18.879(5) 
b (Å) 24.408(5) 
c (Å) 15.375(5) 
α (°) 90 
β (°) 109.862(5) 
γ (°) 90 
V (Å3) 6663(3) 
Z 2 
ρcalc (g/cm3) 1.450 
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μ (mm-1) 0.133 
F (000) 3048 
Crystal size (mm) 0.23 x 0.16 x 0.06 
Radiation wavelength (MoKα) (Å) λ = 0.71073  
Range scanned θ (°) 1.408 to 27.541 
Index ranges ±h, ±k, ±l -24 ≤ h ≤ 23, -31 ≤ k ≤ 31, -19 ≤ l ≤ 18 
Reflections (total) 29872 
Independent reflections 15223 
Completeness (%) 99.5 
Reflections with I>2σ(I) 10937 
Parameters 810 
Rint 0.0361 
R1 [I>2σ(I)] 0.0861 
wR2 [I>2σ(I)] 0.2221 
Goodness-of-fit, S 1.031 
a, b in w = 1/[σ2(Fo2)+(aP)2+(bP)] a = 0.1427, b = 13.807 
Δρmin, max (eÅ-3) -0.97 and 1.06 
 
All the elements useful for this dissertation have been carefully set, but it is necessary to note 
that the model is not complete. Some changes in the future will be taken into account (e.g. 
the calculation of hydrogen atoms on water molecules and their correct agreement in a 
network of hydrogen bonds with that already present). 
5.5.2) STRUCTURE SOLUTION AND REFINEMENT 
The -CD molecule from the isomorphous complex with CSD6 refcode AJUVEG was used as 
a trial model. After removal of the guest molecule (methylparaben) and the freely rotating 
primary hydroxyl groups, the remaining rigid fragment was refined isotropically and the 
remaining atoms were located in successive difference Fourier maps. The structure of the 
complex, including host, guest and water molecules, was refined using full-matrix least-
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squares with program SHELXL-97.7 This model was challenging due to the partial overlap 
of two disordered components of the fluconazole guest molecule related by the 
crystallographic twofold axis. The PART command was used extensively, principally on the 
guest and water molecules, to eliminate false atom connectivities. The phenyl ring geometry 
was maintained using a regular rigid hexagon model (AFIX 66 command) and ten DFIX 
restraints were used to maintain reasonable geometry of the triazole groups.  
In Figure 5.13 two representations of the guest molecule are shown: on the right, the 
partially-overlapped components of guest disorder related by the twofold axis (each with 
site-occupancy factor (s.o.f.) 0.5), and on the left, a single component of guest disorder. 
 
Figure 5.13: Representation of the guest with PART command (left) and without it (right). In the 
image on the right labels were omitted for clarity. 
 
The glucose units are labelled 1 to 7 and each atom has a label ‘XnYm’. ‘X’ is C, O or H; ‘n’ is 
a number from 1 to 8 that represents the atom position; ‘Y’, in this case, is ‘G’ and is the label 
of the cyclodextrin ring; ‘m’ is a number from 1 to 7 and it references the glucose residue. 
The host presented disorder in two primary hydroxyl groups. Those atoms were labelled 
differently for a fast identification (e.g. XnYH and XnYI). In Figure 5.14, the primary oxygen 
atom at C6G2 is disordered over two positions with s.o.f.s of 0.57 for O6GH and 0.43 for 
O7GH. It was possible to find a comparable situation for the atom C6G6 of the glucose unit 
G6. The s.o.f.s of atoms O6GI and O7GI in residue G6 refined to the same values as in the 
case of the disordered component atoms in glucose unit G2. The C-O bond lengths for these 
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two pairs of atoms were fixed with a DFIX restraint at 1.440(2) Å. The large residual electron 
density peak of 1.06 e Å-3 was located near O7GH, but it had no chemical significance. 
 
Figure 5.14: Graphical representation of disordered primary hydroxyl oxygens in the MBCDFLU 
host structure (yellow spots). For simplicity, all hydrogen atoms and water molecules have been 
omitted. 
 
The hydrogen atoms for host and guest were placed geometrically with the ‘generate HFIX’ 
command of the X-Seed interface8 and their Uiso values were maintained in the range 1.2-1.5 
times the thermal parameters of their parent atoms. The O-H bond length of the drug 
molecule was restrained at 0.84(5) Å using the DFIX command. The hydrogen atoms on 
water molecules were not located in difference Fourier syntheses nor completely generated 
due to a high degree of disorder of most of the water oxygen atoms.  
The sum of the s.o.f.s of all the oxygen atoms of water molecules did not agree with the TGA 
result. For this reason, a fixed Uiso value equal to the average of the fully-occupied water 
oxygen atoms was assigned to the atoms with a significantly low electron density. With this 
expedient, the s.o.f. parameters were marginally modified by refinement and the sum of the 
s.o.f.s increased accordingly. The final sum of the s.o.f.s for water oxygen atoms was 10.6 per 
asymmetric unit (i.e. corresponding to 21.2 molecules of water per dimeric complex unit) 
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whereas the thermal analysis yielded a value of 14.2 ± 1.4 per asymmetric unit and thus 28.4 
per dimeric complex unit. As explained above, in paragraph 5.3.3, the more reliable result 
was that obtained by TGA.  
5.5.3) DESCRIPTION OF THE STRUCTURE 
The asymmetric unit of MBCDFLU is composed of a single β-CD molecule, one half of a 
fluconazole molecule and 10.6 water molecules (while the TGA result, as explained above, 
yielded 14.2). The guest molecule is positioned in the host cavity via entry of one of the 
triazole groups from the secondary rim (Figure 5.15). A large cavity is generated by two 
cyclodextrin molecules which are linked at their secondary faces by O-HO hydrogen bonds. 
The phenyl and the hydroxyl groups of the drug molecule are located in the middle of the 
cavity generated by the two CD molecules, the former group lying at the interface between 
the secondary rims.  
          
Figure 5.15: The asymmetric unit of MBCDFLU. In the space-filling structure (right) the water 
oxygens were removed for simplicity.  
5.5.4) HOST CONFORMATION 
In Table 5.4 are listed all the geometric parameters of the host molecule. The parameter l 
measures the distance between each glycosidic atom (O4) and the centroid of the O4-
heptagon. In a regular heptagon, all these distances, must be equal and any variation in their 
values can be attributed to distortion by the encapsulated guest molecule. Similarly, 
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parameters such as D (O4O4distance), Φ (O4O4O4 angle) and d 
(O4O4O4O4 torsion angle) are also useful for understanding the effect of distortion 
on the host ring.  
 
Figure 5.16: β-CD structure in the inclusion complex. For simplicity, all the hydrogen atoms have 
been removed and only one glucoside unit was completely labelled. 
 
Table 5.4: Geometric parameters of the host molecule in MBCDFLU. 
Residue l (Å) D (Å) Φ (°) d (°) αa (Å) D3b (Å) τ1c (°) 
G1 4.878 4.383 127.8 -3.3 -0.071 2.830 10.2 
G2 5.097 4.310 124.5 1.6 -0.041 2.787 11.1 
G3 5.194 4.275 132.9 4.5 0.090 2.795 8.5 
G4 4.833 4.534 130.4 -5.5 0.012 2.786 1.6 
G5 4.951 4.294 122.1 0.4 -0.115 2.760 10.5 
G6 5.292 4.336 131.3 3.6 0.062 2.786 12.6 
G7 4.957 4.437 130.0 -0.7 0.064 2.964 7.6 
a mean e.s.d. 0.004 Å; b mean e.s.d. 0.0077 Å; c mean e.s.d. 0.17° 
The deviations of the O4 atoms from the O4 mean plane, listed in the α column, clearly 
indicate that the O4-heptagon has conserved a high degree of planarity. The D3 parameter 
measures the distances O2∙∙∙O3 involved in intramolecular O-H∙∙∙O hydrogen bonding on 
the secondary rim of the cyclodextrin. The last parameter is the tilt angle (τ1) of each glucose 
ring from a hypothetical cylindrical host geometry. The values show that G4 is less tilted 
than other residues. The proximity of G4 to a triazole group of fluconazole could generate a 
repulsion between the electron densities of the two moieties, modifying the inclination of 
 
82 
the glucose residue. This statement was verified through a comparison between the τ1 data 
listed above and those related to an uncomplexed β-CD molecule.   
5.5.5) HYDROGEN BONDING 
In Figure 5.17 are reported the representations of the intramolecular hydrogen bonds of the 
MBCDFLU complex. It is possible to identify twelve contacts in total:  
 Seven intramolecular H-bonds, located on the secondary rim of cyclodextrin (they 
serve to maintain the ‘round’ macrocyclic-ring shape);  
 Four intermolecular host-host H-bonds that maintain the stability of the crystal 
structure; 
 An intramolecular guest-guest H-bond located between the hydroxyl group and the 
N atom of a triazole group of the fluconazole molecule.  
These interactions are listed in Table 5.5 with their respective labels, distances and angles. 
 
                                      
Figure 5.17: Intramolecular hydrogen bonds for the MBCDFLU complex (hydrogen atoms not 








Table 5.5: Hydrogen bonding interactions in the MBCDFLU inclusion complex. 
Interaction D-H (Å) H∙∙∙A (Å) D∙∙∙A (Å) D-H∙∙∙A (°) 
Intramolecular H-bonds 
O2G1-H9G1∙∙∙O3G7 0.84 2.00 2.830(8) 168 
O2G2-H9G2∙∙∙O3G1 0.84 1.96 2.787(8) 167 
O2G3-H9G3∙∙∙O3G2 0.84 1.98 2.795(8) 165 
O2G4-H9G4∙∙∙O3G3 0.84 1.96 2.786(7) 168 
O2G5-H9G5∙∙∙O3G4 0.84 1.96 2.760(8) 160 
O2G6-H9G6∙∙∙O3G5 0.84 1.95 2.786(8) 170 
O2G7-H9G7∙∙∙O3G6 0.84 2.13 2.964(7) 172 
Intermolecular H-bonds 
O3G5-H3G5∙∙∙O3G4a 0.84 1.95 2.779(6) 170 
O3G6-H3GF∙∙∙O3G3a 0.84 2.04 2.858(8) 164 
O3G7-H3GG∙∙∙O3G2a 0.84 2.03 2.739(7) 142 
O6G5-H8G5∙∙∙O6G7b 0.84 1.98 2.759(9) 153 
Guest 
O16-H16∙∙∙N19 0.84 2.24 2.92(2) 140 
a 1-x, y, 1-z; b ½-x, ½+y, -z.  
5.5.6) CRYSTAL PACKING 
The complex units are packed in a head-to-head type arrangement. The channels are 
extended along the c-axis and are slightly offset. In Figure 5.18 are reported two 






Figure 5.18: Packing diagrams for the MBCDFLU complex: projection along the c-axis [001] 
projection (top) and along the b-axis (bottom). The guest is coloured in green, the host in blue and 
the water oxygen atoms in red.  
 
On the upper section of Figure 5.18 it is possible to see the effects of the C2 space group 
symmetry on the guest molecule. The two-fold axis passes exactly through a fluorine atom 
(F7). 
Evaluating the structure, principally the host-guest interactions and the packing of the 
molecules, it is possible to understand the fast dehydration that characterizes the complex. 
A high degree of disorder is present and very few direct hydrogen bonds are observed 
between the neighbouring CD dimers, thus water positioned between the columns of CD 
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dimers can leave easily from the crystal on its removal from the mother liquor. These 
structural aspects give only a superficial explanation of this propriety; other factors are 
surely concomitant but this aspect of the study has not been thoroughly investigated.  
In Figure 5.19 is reported the asymmetric unit in space-filling representation with two 




Figure 5.19: Space-filling representation of the asymmetric unit of MBCDFLU with a sectioned 
view of the host. 
5.5.7) COMPARATIVE PXRD  
In Figure 5.20 is reported the comparison between an experimental PXRD pattern of 
MBCDFLU and the one calculated using the program LAZY PULVERIX9 with the data of the 
model. The traces match with a high level of agreement. The slight shift of the red pattern 
towards higher angular values in Figure 5.20 could be attributed to the collapse of the 
crystals during the PXRD analysis and contraction of their unit cells due to their gradual 
dehydration. The sample used to record the experimental trace was obtained by the co-





Figure 5.20: Calculated and experimental PXRD patterns for MBCDFLU. 
 
5.6) SOLID-STATE X-RAY ANALYSIS OF TBCDFLU 
5.6.1) DATA- COLLECTION AND SPACE GROUP DETERMINATION 
The data-collection on this crystal was previously performed at the temperature of 173(2) K 
by the Chemistry Honours student Ms Zakiena Hoossen in 2016.2 The complex structure 
was resolved with a good final residual factor (R1 ~0.07) but poorly-matching experimental 
and calculated PXRD traces, mainly due to the small mass of the complex sample available. 
In the present study, the work of Ms Hoossen was replicated and, as shown in this chapter, 
the β-cyclodextrin inclusion complexes with fluconazole were considerably more thoroughly 
investigated. The data-collection on TBCDFLU was recorded at the temperature of 173(2) K. 
The crystal intensities were collected with a Bruker KAPPA APEX II DUO single crystal X-
ray diffractometer. The frames were integrated with SAINT3 and the multi-scan method was 
used to calculate the absorption corrections using software program SADABS.4 The data 
were analysed with XPREP;5 the crystal system was found to be triclinic and the space group 
P1, since the host molecule is chiral. 
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5.6.2) STRUCTURE SOLUTION AND REFINEMENT 
A trial model for structure solution was obtained by isomorphous replacement using the 
rigid skeleton of the -CD dimer extracted from the crystal structure of a complex (CSD8 
refcode VUYGUT) crystallizing in P1 with unit cell parameters very similar to those of the 
new fluconazole complex. The intensity data displayed a small level of twinning which was 
overcome during refinement of the structural model using full-matrix least-squares 
implemented in SHELXL-97.7 The remaining atoms of the host molecule, as well as the guest 
and water molecules were revealed in subsequent difference electron density Fourier maps. 
Non-hydrogen atoms were refined isotropically initially and after convergence of the Uiso 
values, anisotropic refinement followed.  The residual factor (R1), with this procedure and 
the fixing of water molecules, was very good (8.08%) for a structure of this complexity. All 
the data-collection and refinement parameters are reported in Table 5.6. 
This structure did not present all the modelling difficulties caused by the disorder or 
symmetry encountered with MBCDFLU. In TBCDFLU the only slight degree of disorder was 
associated with water molecules. The hydrogen atoms were refined isotropically with a Uiso 
value in the range 1.2-1.5 times those of their parent atoms. The hydrogen bond network 
between the host structure and the water molecules was partially fixed with DFIX restraints 
to avoid problems caused by disorder. 
The total count of the water molecules of the model agreed with the estimate from TGA. The 
thermoanalytical study revealed the presence of 25.8 ± 1.1 water molecules per asymmetric 
unit (two host molecules, one guest molecule and water molecules). The total sum of the 
site-occupancy factors (s.o.f.s) of the water oxygen atoms in the model was 27.3. The two 
results were consistent within experimental error and for this reason it was possible to 
accept the complex formula derived by the crystallographic model. 
 
Table 5.6: Data-collection and refinement parameters for TBCDFLU.  
Abbreviated formula 2 β-CD ∙ FLUCONAZOLE ∙ 27.3 H2O 
Complex formula (C42H70O35)2 ∙ C13H12ON6F2 ∙ 27.3 H2O 
Formula weight (g mol-1) 3067.48 
Data collection temperature (K) 173(2) 
Crystal system triclinic 
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Space group P1 
a (Å) 15.331(3) 
b (Å) 15.392(3) 
c (Å) 17.972(3) 
α (°) 113.613(3) 
β (°) 99.410(3) 
γ (°) 102.597(3) 
V (Å3) 3640.0(12) 
Z 1 
ρcalc (g/cm3) 1.3992 
μ (mm-1) 0.128 
F (000) 1636 
Crystal size (mm) 0.21 x 0.15 x 0.05 
Radiation (Mo Kα) (Å) λ = 0.71073 
Range scanned θ (°) 1.29 - 25.7 
Index ranges ±h, ±k, ±l -18 ≤ h ≤ 18, -16 ≤ k ≤ 18, -21 ≤ l ≤ 0 
Reflections (total) 26399 
Independent reflections 13586 
Reflections with I > 2σ(I) 11090 
Parameters 1887 
Rint 0.0617 
R1 [I>2σ(I)] 0.0646 
wR2 [I>2σ(I)] 0.1595 
Goodness-of-fit, S 1.029 
a, b in w = 1/[σ2(Fo2)+(aP)2+(bP)] a = 0.1050, b = 3.4655 
Δρmin, max (e Å-3) -0.44, 0.79 
 
5.6.3) DESCRIPTION OF THE STRUCTURE 
The TBCDFLU complex is composed of a dimeric unit forming a head-to-head cage with the 
two cyclodextrins hydrogen bonded via their secondary rims (Figure 5.21). The molecules 
that comprise the unit are two β-CD molecules, one molecule of fluconazole and 27.3 
molecules of water. The TGA revealed the presence of 25.8 ± 1.1 water molecules per 
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asymmetric unit. The triazole groups are inserted inside the hydrophobic cavities of the 
cyclodextrins, having entered from the wider secondary rims. 
 
             
Figure 5.21: Two representations of the asymmetric unit of TBCDFLU (water molecules are 
omitted for simplicity). 
 
5.6.4) HOST CONFORMATION 
In the case of TBCDFLU, the dimer is formed by two crystallographically independent 
cyclodextrin rings that are designated A and B. Such as MBCDFLU example, the glucose 
units are labelled 1 to 7 and each atom has a label ‘XnYm’, as in the example shown in Figure 
5.14. ‘X’ is C, O or H; ‘n’ is a number from 1 to 8 that represents the atom position; ‘Y’, in this 
case, is A or B and is the label of the cyclodextrin ring; ‘m’ is a number from 1 to 7 and it 





                        
Figure 5.22: Schematic representation of the ‘XnYm’ system of labelling for TBCDFLU (a single 
glucose residue on the left and the host dimeric unit on the right). Hydrogen atoms and water 
molecules are omitted for simplicity. 
 
Table 5.7: Geometric parameters of the host molecule in TBCDFLU. 
Residue l (Å) D (Å) Φ (°) d (°) αa (Å) D3 (Å) τ1b (°) 
A1 5.017 4.531 132.95 0.53 -0.016 2.84(1) 8.5 
A2 4.817 4.300 126.74 0.08 -0.007 2.79(1) 3.7 
A3 5.124 4.415 124.75 -1.54 0.016 2.70(1) 4.9 
A4 5.230 4.246 130.85 2.07 0.008 2.81(1) 11.0 
A5 4.899 4.555 134.07 -0.71 -0.031 2.84(1) 7.8 
A6 4.844 4.302 120.60 -0.46 0.020 2.82(1) 12.7 
A7 5.351 4.293 130.01 0.19 0.010 2.79(1) 4.8 
B1 5.030 4.391 130.14 0.68 0.000 2.71(1) 12.7 
B2 4.900 4.401 129.92 0.18 -0.009 2.75(1) 3.3 
B3 5.005 4.377 123.23 -1.76 0.012 2.79(1) 6.1 
B4 5.240 4.215 132.00 2.74 0.008 2.82(1) 7.8 
B5 4.898 4.569 130.98 -1.97 -0.031 2.82(1) 6.9 
B6 4.903 4.265 124.27 0.96 0.029 2.80(1) 14.3 
B7 5.209 4.324 129.42 -0.70 -0.010 2.88(1) 5.7 




The distance between each O4 atom and the centroid of each cyclodextrin ring (l) and the Φ 
angles are consistent with those in the MBCDFLU case: the encapsulation of the guest 
distorted the host rings. However, the torsion angles (d) are smaller than in the MBCDFLU 
case (see Table 5.4). For these reasons, it is possible to confirm that the host ring is distorted 
but the O4-heptagon remains planar and this should be confirmed by α, the parameter that 
represents the deviation of a O4 atom from the mean O4-plane, that does in fact have a very 
small range (from -0.031 to 0.029 Å). The D3 parameter, that measures the O2O3′ 
distances, is always consistent with the average length for a theoretical hydrogen bond 
interaction. Compared to the MBCDFLU glucose tilt angles, the τ1 parameters for TBCDFLU 
are quite similar.  
5.6.5) HYDROGEN BONDING 
In Figure 5.23 the representations of the molecular moieties in TBCDFLU’s asymmetric unit 
are reported (for clarity the labels of host molecules are not shown). The hydrogen bond 
network for the host dimer includes all the interactions with the 27.3 water molecules found 
in the model; they were not reported in the figures of this subparagraph for underlining 
better the host-host interactions. The guest is bonded to the host only with weak 
interactions; no host-guest hydrogen bonds were found in the model. The intramolecular 
host hydrogen bonds are very important for the complex: those between O2 and O3′ atoms 
maintain the round shape of the two cyclodextrin molecules and the intermolecular bonds 
between the secondary rims of the two macrocycles are fundamental in stabilising the 
dimeric unit (in Figure 5.23 all these bonds are represented with blue dotted lines). In Table 





                      
Figure 5.23: Intramolecular and intermolecular hydrogen bonds for the TBCDFLU complex (host 
on the left side and guest on the right side). Blue dotted lines indicate the hydrogen bonds of the 
asymmetric unit and red dotted lines represent the hydrogen bonds between the dimeric cages. For 
simplicity labels were removed. 
 
Table 5.8: Hydrogen bonding interactions in the TBCDFLU inclusion complex. 
Interaction D-Hi (Å) H∙∙∙Aii (Å) D∙∙∙A (Å) D-H∙∙∙Aiii (°) 
Intramolecular host H-bonds 
O2A1-H2A1∙∙∙O3A7 0.84 2.06 2.84(1) 154 
O3A1-HAA1∙∙∙O2A2 0.80 1.90 2.79(1) 162 
O2A3-H9A3∙∙∙O3A2 0.84 1.88 2.70(1) 171 
O2A4-H2A5∙∙∙O3A3 0.84 2.04 2.80(1) 152 
O3A4-HAA4∙∙∙O2A5 1.00 1.80 2.84(1) 160 
O3A5-HAA5∙∙∙O2A6 1.00 1.80 2.83(1) 175 
O3A6-HAA6∙∙∙O2A7 0.85 1.96 2.79(1) 164 
O2B2-H2B2∙∙∙O3B1 0.80 1.80 2.71(1) 165 
O3B2-H3B2∙∙∙O2B3 0.84 2.12 2.76(1) 133 
O3B3-H3B3∙∙∙O2B4 0.80 2.03 2.79(1) 160 
O3B4-H11∙∙∙O2B5 0.84 1.99 2.83(1) 174 
O3B5-H12∙∙∙O2B6 0.84 2.10 2.82(1) 144 
O3B6-H15∙∙∙O2B7 0.80 2.01 2.80(1) 169 
O3B7-H17∙∙∙O2B1 0.80 2.18 2.88(1) 146 
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Intermolecular host-host H-bonds 
O2A2-H9A2∙∙∙O3B2 0.84 1.91 2.74(1) 169 
O3A3-H3A3∙∙∙O2B7a 0.84 1.96 2.78(1) 165 
O2A5-H4∙∙∙O3B5 0.80 1.90 2.70(1) 175 
O2A6-H7∙∙∙O3B6 0.84 1.97 2.80(1) 167 
O2A7-H8∙∙∙O3B7 0.80 1.97 2.73(1) 159 
O3A7-H9∙∙∙O3B7 0.80 2.43 3.17(1) 152 
O3B1-H9B1∙∙∙O2A1 0.80 2.28 3.00(1) 149 
O2B4-H10∙∙∙O2A4 0.80 2.40 3.13(1) 151 
O6A1-H8A1∙∙∙O6B4b 0.84 1.87 2.74(1) 172 
O6A3-H8A3∙∙∙O6A7a 0.80 2.02 2.82(1) 174 
O6B2-H8B2∙∙∙O6B5c 0.80 1.94 2.74(1) 176 
Intramolecular guest H-bond 
O10-H10A∙∙∙N13 0.84 2.22 2.85(1) 133 
i mean e.s.d. 0.005 Å; ii mean e.s.d. 0.005 Å; iii mean e.s.d. 2.5°; a x, -1+y, z; b 1+x, 1+y, 1+z; 
c 1+x, y, z.  
It is possible to observe that all the D∙∙∙A contact distances are similar with the exception of 
three intermolecular host H-bonds that have an average value > 3.00 Å (O3A7-H9∙∙∙O3B7, 
O3B1-H9B1∙∙∙O2A1 and O2B4-H10∙∙∙O2A4). As in the MBCDFLU case, host-guest H-bond 
interactions are totally absent and an intramolecular guest H-bond is present, with 
comparable parameter values.  
5.6.6) CRYSTAL PACKING 
The cyclodextrin dimers are assembled in the ‘intermediate’ packing arrangement (‘brick-
work’ or ‘brick-cage’ arrangement).10 Two representations are shown in Figure 5.24. 
Hydrogen atoms were removed for clarity but the oxygen atoms of water molecules were 





Figure 5.24: Two representations of TBCDFLU crystal packing. In green is reported the fluconazole 
molecule, in blue the cyclodextrin dimer and in red the oxygen atoms of the water molecules. On 
the left side is reported the view normal to the bc-face (from which the ‘brick-cage’ arrangement is 
very clear) and on the right side is reported the [001] projection of the crystal structure. 
 
In Figure 5.25 is reported the space-filling representation of a TBCDFLU cage which 
highlights the effective filling of the cavity by the guest. Several glucoside residues were 
removed to allow the visualisation of the fluconazole molecule. 
 
 
Figure 5.25: Space-filling representation of TBCDFLU (the upper cyclodextrin ring is the A 





5.6.7) COMPARATIVE PXRD 
The calculated PXRD trace from the refined model and the experimental pattern are 
reported in Figure 5.26. The degree of agreement is very high, corresponding peaks showing 
very similar profiles. However, it is also evident that several low-angle peak intensities in 




Figure 5.26: Calculated and experimental PXRD patterns for TBCDFLU. 
 
5.7) PHASE SOLUBILITY ANALYSIS  
The phase solubility studies were carried out only with fluconazole and β-CD and were 
performed according to the method described by Higuchi and Connors.11 These authors 
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classified phase solubility profiles into two broad types, each with more than one sub-type, 
as follows: 
A. The A-type presents an increase in the solubility of the drug with an increase in CD 
concentration and it can be divided into three sub-types. AL has a linear increase, AP deviates 
positively from linearity and AN has a negative curve deviation due to a change in the physical 
nature of the solution. 
B. The B-type profile indicates the formation of an insoluble complex in the solution. The sub-
types (BL and BS) indicate, respectively, the formation of a completely insoluble complex and 
a complex with limited solubility. 
Several series of dilutions of β-CD solutions (2, 4, 8, 12, 16, 20 mM) in water:EtOH (99:1 
v/v) were prepared and an excess of fluconazole was added to a set of vials, each containing 
3 ml of solution. The contents of the vials were magnetically stirred at 500 rpm for 36 h at 
the temperature of 299 ± 1 K. Each solution was then filtered through a 45 μm nylon filter 
and analysed by UV-Vis spectrophotometry. Measurements were performed in triplicate and 
average values of the absorbances at max = 260 nm were recorded. The concentration of API 
was determined from the calibration curve in Figure 5.27 (details of the procedures for 
obtaining the calibration data are provided in Chapter 2). 
 
 




With the Beer-Lambert equation (10), the extinction coefficient (ε0) of fluconazole was found 
to be 627.85 M-1 cm-1. This means that the API is strongly UV-active. 
𝐴 = 𝜀 𝑐𝑙     (10) 
Each β-CD solution containing the fluconazole was filtered into a clean vial and rapidly 
diluted 1:20 with a solution of water:EtOH (99:1 v/v). The phase solubility profile (Figure 
5.28) was based on the average of three different absorbance measurements per solution.  
 
 
Figure 5.28: Phase solubility profile for the complex of β-CD and fluconazole. Notice that the 
requirement of linearity (in which the stoichiometric host-guest ratio is 1:1), useful for the 
calculation of the association constant Kc, is present only at a low concentration of host and guest. 
 
The profile of phase solubility had a linear trend at low concentration, revealing a 1:1 
complexation ratio between -CD and fluconazole in solution. At high concentrations, there 
was a negative deviation from linearity with a second order polynomial trend. It indicated 
the formation of a complex with limited solubility.  This result may be compared with results 
reported in a previous paper12 where the phase solubility of fluconazole in β-CD using the 
same experimental procedure in pure water was investigated. The data were significantly 
different due to the change of solvent but the trend was very similar. The intrinsic solubility 
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(S0) of the API at 299 ± 1 K (whose value is 1.651 mM) was extrapolated from the phase 
solubility profile. With these data it was possible to calculate the association constant (Kc) 
for the complex. This parameter was evaluated using the equation (11), which is applicable 
if the concentration is low and the stoichiometry of the CD-drug complex is 1:1. 
𝐾 =  
 ( )
      (11) 
 
The calculated value of Kc is 27.2 M-1. 
The association constant value reported in the previous paper12 was very close to this result 
(22.2 M-1). It is also necessary to bear in mind that the experimental conditions were very 
close to those employed in this work. The solutions were stirred in pure water for 48 h at 
298 ± 1 K and they were analysed with a UV-Vis spectrometer (λ = 261 nm). The only 
difference was the concentration range spanned by the sets of solutions: in this work, the 
range was 2 mM to 20 mM, while in the previously reported one it was only 0 mM to 4 mM. 
The tendency of the complex is overall towards a B type, according to the Higuchi and 
Connors method. This means that at high concentrations the complex formed is less soluble 
than the one at low concentrations and for this reason the sub-type is BS.   
In the 20 mM β-CD solution, the concentration of fluconazole was 3.04 mM. The solubility 
of fluconazole in the 20 mM solution of β-CD was 0.9317 g/l. This result was compared with 
the fluconazole solubility in pure water (~1 mg/l)1 and a ratio was calculated. The solubility 
enhancement factor of fluconazole was thus ~900. For this reason, it was possible to confirm 
a very significant improvement in the solubility of the API in the β-CD solution although the 
host-guest binding is very weak in solution. This result could be used in a future application 
to drug delivery. The β-CD was not the best solubiliser possible for a phase solubility 
experiment, since other types of cyclodextrins are more adapted for this analysis (e.g. 
HPBCD). The whole work in this chapter focuses on the host compound β-CD and therefore 
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γ-CYCLODEXTRIN INCLUSION OF FLUCONAZOLE 
 
                                       
 
   
6.1) EXPERIMENTAL 
2 mg (6.53  10-6 mol) of fluconazole were kneaded for ~15 minutes with 9.31 mg (7.18  10-
6 mol) of γ-cyclodextrin. A minimum amount of water (~25 μl) was added to minimise the 
quantity of solvent inside the system. The white powder which resulted from kneading was 
analysed using PXRD. A calculated trace from the isostructural series for γ-CD complexes1 
was compared with the trace experimentally recorded and it was concluded that the product 
was an authentic -CD complex containing fluconazole, hereafter referred to as GCDFLU. In 
Figure 6.1 are reported comparative PXRD traces of GCDFLU and an isostructural -CD 
inclusion complex1,2 to emphasise the effective success of the current kneading experiment. 
The close match of the common PXRD peaks not only indicates formation of an inclusion 
complex between -CD and FLU but enables assignment of its crystal system (tetragonal), 
space group (P4212) and prediction of its unit cell dimensions as a ~ 23.8 Å, c ~ 23.1 Å. This 





Figure 6.1: PXRD traces of GCDFLU (red) and an isostructural γ-CD inclusion complex (blue).1, 2 
The two complexes belong to the space group P4212. 
 
The same quantities of raw material were used for a co-precipitation attempt. The γ-CD was 
dissolved in ~400 μl of water at 60 °C with a gentle stirring. The fluconazole was added in 
small aliquots (~0.5 mg every hour) and the solution was maintained at 60 °C and stirred 
overnight (~12 h). The solution was filtered through a 0.45 μm nylon filter into a pre-heated 
vial and it was immediately incubated in a Dewar flask filled with water at 60 °C. The system 
was covered with alternate sheets of tinfoil and cotton wool to ensure the longest duration 
of incubation possible (~2 days). After this period, very small, tetragonally-shaped 
colourless crystals with square cross-section were obtained. The vial was exposed to the open 
air for two more days to permit the evaporation of solvent and the consequent enlargement 
of these crystals.  
Referring to the situation found in Paragraph 5.1 (Chapter 5), a comparison might be done 
here. Two more attempts with different temperatures of incubation were carried out to 
determine the dependence of the crystalline form of the new complex on the experimental 
conditions. A vial prepared for a co-precipitation attempt was cooled to an incubation 
temperature of 45 C and a second replica was placed directly in water at ~ 20 °C. The results 
of all the experiments, independently of the temperature, yielded the same type of crystal 
complex. For this reason, it was possible to conclude that the incubation temperature was 
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not critical for isolating the single crystals of complex GCDFLU. The incubation procedure 
was used only to promote an enlargement of the size of the crystals.  
6.2) NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
The stoichiometric ratio between γ-CD and fluconazole in the complex crystals was 
determined by 1H-NMR spectroscopy. The 1H-NMR spectrum of GCDFLU in DMSO-d6 is 
reported in Figure 6.2 and in Table 6.1 all the peak integrations are presented. 
 
Figure 6.2: 1H-NMR spectrum of GCDFLU in DMSO-d6. 
 
Table 6.1: 1H-NMR peak integrations for GCDFLU. 
Proton δ (ppm) Multiplicity J (Hz) Integration 
Experimental/ 
Theoretical 
HE 8.32 s / 2.00* 1.00 
HF 7.79 s / 1.73 0.87 
HB 7.14-7.24 m / 2.00 1.00 
HA 6.85-6.91 t of d 6.30; 1.50 0.83 0.83 
HD 6.32 s / 1.08 1.08 
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H8 5.66-5.76 d (x 2) 5.40; 2.10 14.30 0.89 
H1 4.85-4.94 d 3.00 7.21 0.90 
HC 4.53-4.78 q 42.30; 10.80 5.09 1.27 
H7 4.43-4.51 t 4.20 7.03 0.88 
H3, H5, H6 3.50-3.71 m / 28.55 0.89 
H4 3.33-3.41 t 7.5 10.08 1.26 
*reference integral 
From the data above, it is evident that the integration of HE (for the fluconazole) and the 
sum of the principal CD signals (H3, H4, H5 and H6) were in a 1:1 ratio. It was, however, 
difficult to assign certain signals. For the H8 protons there was the presence of two different 
doublets; the proton assignment was not totally clear. The signal for H2 completely 
overlapped with the one of water (3.2-3.3 ppm) and for this reason it was impossible to 
include it in the analysis. For accuracy, the last group of signals in the range 2.4-2.6 ppm 
was not analysed because it originated from the solvent (DMSO-d6). 
6.3) THERMAL ANALYSIS 
Hot Stage Microscopy (HSM), Thermogravimetric Analysis (TGA) and Differential Scanning 
Calorimetry (DSC) were carried out on GCDFLU to evaluate all the possible behaviours at 
elevated temperatures. 
6.3.1) HSM 
A HSM experiment was conducted with a heating rate of 10 °C/min to establish the thermal 
stability of the complex GCDFLU. In Figure 6.3 is reported the HSM experiment described 
above; the crystal was removed from mother liquor, put on a clean slide and covered with a 
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The crystal presented parallel cracks at low temperature (31 °C) that increased in number 
until 122 °C, the point at which the crystal began to dehydrate, as indicated by the 
appearance of bubbles. After the dehydration (122-200 °C) the crystal was stable until 278.2 
°C (degradation point). It was possible to confirm that GCDFLU is thermally stable because 
the temperature of degradation of the complex was higher than both the melting point of 
fluconazole (138-140° C) and that of the degradation point of γ-cyclodextrin (267 °C). 
6.3.2) TGA AND DSC  
Thermogravimetric analysis was the only technique that was capable of measuring the exact 
number of water molecules per complex molecule in the crystal. Both TG and DSC traces are 
reported in Figure 6.4. The two curves confirmed the HSM test, showing only the 
dehydration event as a mass loss (TGA) and an endothermic peak (DSC). The decomposition 




Figure 6.4: TG (red) and DSC (green) curves for GCDFLU. 
 
The two curves shown in Figure 6.4 were obtained from an average of five different analyses 
per technique. To establish the average number of water molecules per complex unit, 
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expression (12) was used. The percentage mass loss is 15.0 % ± 0.5 % and the stoichiometric 
ratio between host and guest from 1H-NMR data is 1:1.  
 
𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠 % =  
 × 
  (  × )
    ×  100      (12) 
 
The average number of water molecules was n = 15.7 ± 0.5. Thus, the formula for the 
complex GCDFLU can be expressed as -CDFLU15.7H2O. 
6.4) FOURIER TRANSFORM INFRARED SPECTROSCOPY 
The FT-IR technique was not a diagnostic test but was useful to verify the complexation of 




Figure 6.5: FT-IR spectra of the GCDFLU inclusion complex (red trace), γ-CD (green trace) and 




Notable observations include:  
 the glycosidic bond stretching peak at ~1030 cm-1 occurred at the same frequency in 
both the host spectrum and the GCDFLU complex spectrum (also the relative 
transmittances were equal);  
 the triazole aromatic bond stretching in the fluconazole spectrum (~1620 cm-1) was 
present, with a lower intensity and it overlapped a signal of the γ-CD, also in the 
GCDFLU spectrum; 
 the broad signal of water at 2990-3675 cm-1 had a bigger relative intensity in the 
complex spectrum than in the γ-CD spectrum; 
 the signals in the range 632-873 cm-1 and the aromatic peaks at 1170-1500 cm-1 in the 
complex spectrum had a bigger relative transmittance than their counterparts in the 
γ-CD spectrum due to the API influence. 
With some exceptions listed above, the GCDFLU spectrum might easily be superimposed 
on the γ-CD spectrum (Figure 6.6). This was a very important result because it was a 
clear signal of the complexation of the API. 
 
 





6.5) X-RAY ANALYSIS  
The instrument used for the collection of the crystal reflection intensities was a Bruker 
KAPPA APEX II DUO single crystal X-ray diffractometer. The frames were integrated with 
the Bruker SAINT3 software package and the data were corrected for absorption effects using 
the multi-scan method (SADABS).4 The crystal system was found to be tetragonal and the 
space group P4212 (as predicted using the PXRD technique) and subsequently confirmed by 
the program XPREP.5  
The data-collection was performed at 100(2) K in order to obtain the best resolution, as it is 
known that the guest is frequently not discernible in γ-CD complex structures analysed at 
higher temperatures. The latter is due to the large size of the γ-CD cavity and its requirement 
of fourfold crystallographic rotational symmetry (and hence that of the guest molecule as 
well). These features thus promote guest disorder. The host structure was solved using 
isomorphous replacement with a CSD6 structure as a trial model (SIBJAO). The refinement 
was carried out with SHELXL-977 though the X-Seed interface.8 The asymmetric unit of the 
complex consists of three, crystallographically independent host fragments (each 
comprising two glucose units, guest and water molecules). When the fourfold rotation 
operation is applied to the three host fragments, three independent host molecules (A, B, C) 
are generated.  
The water molecules are principally located between the host molecules. The guest was 
physically complexed by the host but the electron density inside the cavity was very low 
(maximum ~ 1.03 eÅ-3). The peaks had poor intensity values and they were severely 
fragmented. This was associated with the effect of the high symmetry (a fourfold rotation 
axis along the crystallographic c-axis) and it led to a classical situation for γ-CD complexes 
structures: the impossibility of resolving the structure to a satisfactory level of refinement. 
Another problem was the total count of water molecules inside the structure. Although the 
number of water molecules contained in the structure was calculated from TGA to be 15.7 
molecules, the total sum of the s.o.f.s (site-occupancy factors) for the oxygen atoms related 
to water molecules was calculated to be 11.7. Due to these typical shortcomings, all the 
existing data for GCDFLU (including the complex formula in Table 6.2) were obtained from 
the analysis described above. The evidence for the difference between the thermal analysis 
estimate and that for the refined model is recorded in the checkCIF report file, located in the 
Appendix section. Consequently, an important (but expected) “A alert” refers to a significant 
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discrepancy between the calculated and the experimental formula weights. In the electronic 
Appendix are provided all the files related to the current structure for the sake of 
completeness. 
In Table 6.2 are reported the data-collection and refinement parameters for the GCDFLU 
complex. 
 
Table 6.2: Data-collection and refinement parameters for GCDFLU. 
Abbreviated formula γ-CD ∙ FLU∙ 15.7 H2O  
Complex formula C48H80O40 ∙ C13H12F2N6O ∙ 15.7H2O 
Formula weight (g mol-1) 1886.3 
Data collection temperature (K) 100(2) 
Crystal system Tetragonal 
Space group P4212 
a (Å) 23.737(3) 
c (Å) 23.155(3) 
V (Å3) 13047(5) 
Z 6 
ρcalc (g/cm3) 1.440 
μ (mm-1) 0.131 
F (000) 6018.0 
Crystal size (mm) 0.22 x 0.24 x 0.26 
Radiation (Mo Kα) λ = 0.71073 
Range scanned θ (°) 1.23 – 24.98 
Index ranges ±h, ±k, ±l -11 ≤ h ≤ 28, -27 ≤ k ≤ 19, -27 ≤ l ≤ 27 
Reflections (total) 48809 
Independent reflections 11480 
Reflections with I > 2σ(I)  8100 
Parameters 644 
Rint 0.0518 
R1 [I > 2σ(I)] 0.1286   
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wR2 [I > 2σ(I)] 0.3546 
Goodness-of-fit, S 1.477 
a, b in w = 1/[σ2(Fo2)+(aP)2+(bP)] a = 0.2, b = 0.0 
Δρmin, max (e Å-3) -0.96 and 1.03 
 
The PART command was used extensively to remove false atom connectivities on guest and 
water molecules. In Table 6.3, the primary oxygen atoms disordered over two positions are 
reported (with their relative s.o.f.s). The C-O bond lengths for these pairs of atoms were fixed 
with a DFIX restraint at 1.440(1) Å (except for C6G1-O6G1) whereas the distances between 
the oxygen atoms of water molecules were fixed with a DFIX restraint at 2.80(5) Å. Two 
pairs of water molecules affected by disorder were O9O11 and O6O12 (with s.o.f.s of 0.85 
and 0.67, respectively). For the O9O11 pair it was necessary to impose a DFIX restraint. 
All the disordered oxygen atoms are shown graphically in Figure 6.7.  
The hydrogen atoms of the host molecules were placed geometrically with the ‘generate 
HFIX’ command of the X-Seed interface8 and their Uiso values were maintained in the range 
1.2-1.5 times the thermal parameters of their parent atoms. The residual positive electron 
density peak of 1.03 Å-3 was located near O7G5. 
 
Table 6.3: Primary oxygen atoms disordered over two positions with relative s.o.f.s and indication 
of the imposition of a restraint on the C-O bond.  
C atom O atom DFIX s.o.f. 
C6G1 
O6G1 no 0.53 
O7G1 yes 0.47 
C6G3 
O6G3 yes 0.68 
O7G3 yes 0.32  
C6G5 
O6G5 yes 0.69 






Figure 6.7: Graphical representation of disordered primary oxygen atoms in GCDFLU host 
structure (yellow spheres). Green spheres represent disordered water molecules. For simplicity, 
only the asymmetric unit is shown and all hydrogen atoms have been omitted. 
 
The three independent molecules (A, B and C) form a channel packing arrangement. Each 
channel is centred on the fourfold rotation axis (in turn parallel to the crystallographic c-
axis). When the structure is viewed along the b-axis it is possible to notice a slight vertical 
shift between the channels. This arrangement is typical of the space group P4212 for -CD 
complex crystal structures and it is reported in Figure 6.8. The typical interactions that 
maintain the host molecule arrangement are O-HO hydrogen bonds. In Figure 6.9 a 
schematic representation of the host channels along the crystallographic b-axis is shown. 
The O-HO hydrogen bond interactions occur between the respective cyclodextrin rims in 





Figure 6.8: Channel structure of γ-CD in GCDFLU viewed nearly parallel to the c-axis (left) and 
along the b-axis (right). The image on the right has been coloured in order to emphasize the shift 
between channels.  
 
              
Figure 6.9: Schematic ABC packing motif of γ-cyclodextrin molecules for GCDFLU viewed along 
the a-axis. (On the right side the red dots represent the oxygen atoms of water molecules). 
 
Due to the absence of a complete model from the single crystal X-ray analysis, it was not 
justified to compare a calculated PXRD pattern with the one obtained from the complex 
prepared by kneading, the latter being reported in Figure 6.10. This figure shows the traces 





Figure 6.10: PXRD pattern of GCDFLU obtained by kneading (red), compared with pure γ-CD 
(blue) and fluconazole (black) PXRD patterns. Traces have been mathematically rescaled to 
facilitate the comparison. 
 
Although the guest molecule cannot be visualised, the analyses carried out have revealed the 
complete stoichiometric formula of the hydrated inclusion complex and, from single crystal 
X-ray data, it was possible to be able to describe completely the host arrangement in the 
crystal and the role of the water molecules. From a pharmaceutical point of view, the data 
accumulated are very valuable since the complex has potential application for drug delivery. 
However, the data collected are not sufficient to fully express this potential. For this reason, 
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A summary of all the results obtained in this study together with further comments are 
presented in this chapter. Two known active pharmaceutical ingredients (APIs) of 
widespread use were modified via crystal engineering and supramolecular derivatization 
techniques. Four cyclodextrin (CD) inclusion complexes were isolated. A full 
characterization, including single crystal X-ray structures, was carried out for two CD 
complex crystals. In the other cases, limitations of molecular disorder prevented full 
structural characterization, but under these conditions the best possible X-ray analyses were 
performed.  
7.1) SULFASALAZINE 
This anti-inflammatory drug presented the phenomenon of tautomerism. It was possible to 
prepare and exploit an amine (A-SSZ) and an imine (I-SSZ) form of the drug. Both forms 
were isolated via re-crystallization in a proper solvent. A-SSZ (CCDC refcode QIJZOY) was 
stable in absolute ethanol 98% (EtOH) or pure 2-butanone (methyl ethyl ketone, MEK) and 
I-SSZ (CCDC refcode QIJZOY01) was stable in acetone and tetrahydrofuran (THF). Both 
tautomers were orange crystalline powders (I-SSZ had a darker colour than A-SSZ). 
Several attempts were made to study the co-crystallization of both SSZ tautomers with a 
large number of co-formers. Attempts with lidocaine (an anaesthetic API), urea and citric 
acid turned out to be the most relevant. Only the products from experiments with A-SSZ 
were analysed by PXRD (due to their crystalline character) since products obtained using I-
SSZ were all amorphous. The results showed an uncommon effect derived from LAG 
(Liquid-Assisted Grinding) that induced A-SSZ to transform into I-SSZ during the grinding 
process (the latter was conducted in a solvent appropriate to each tautomer). During this 
process, the specific co-former being employed for possible co-crystallization became 
amorphous. This unexpected effect undermined efforts to achieve the desired reactions, and 
for this reason no new co-crystal phases were obtained with SSZ. Certainly, further 
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experiments such as mechanochemical co-grinding would be appropriate for understand 
this SSZ behaviour. To obtain a single crystal, many attempts were carried out with very slow 
crystallization techniques in solution (low temperatures or evaporation rates of solvents) 
trying to avoid the formation of the amorphous phase observed with the mechanochemical 
approach. A large number of experiments, with compounds listed above, were carried out 
for a total of 68 attempts. These processes required some months of work and, for this reason 
of time constraints, further experiments were not performed and they should be carried out 
in the future. 
A cyclodextrin inclusion complex of γ-CD with SSZ was isolated when the CD was reacted 
with the tautomer I-SSZ. From thermogravimetric (TG) analysis it was possible to obtain 
the water mass loss (13.4% ± 0.1 %) and hence calculate the number of water molecules 
contained in each complex structural unit (n = 15.0 ± 0.3). The stoichiometric ratio between 
host and guest was confirmed as 1:1 by 1H-NMR analysis. Due to the lack of single crystals 
of the complex it was possible to determine only the full stoichiometric chemical formula of 
the complex, namely C48H80O40  C18H14O5N4S ∙ 15 H2O. The degradation point of this crystal 
was found to occur at a temperature of 240 °C. 
7.2) FLUCONAZOLE 
Due to the presence in the literature of several reports of co-crystals of this antifungal API, 
only attempts to include the drug in CDs were carried out. Three CD inclusion complexes 
were isolated and fully characterized: two with β-CD and one with γ-CD. 
The two inclusion complexes with β-CD were obtained simply by changing the concentration 
of the drug or the temperature of the medium in which the crystallization was performed. 
Two distinct single crystals were analysed using SCXRD and two different structural models 
were elaborated. The first structure (partially analysed in a previous study2 in 2016), was 
found to be triclinic (TBCDFLU) and it was re-modelled and completely refined. The second 
was found to be monoclinic (MBCDFLU). The packing arrangements in these crystal forms 
were completely different, namely a brick-cage packing for TBCDFLU and head-to-head 
channel packing for MBCDFLU. The thermogravimetric analysis was problematic due to the 
relatively rapid loss of water of crystallization from these complexes. As a preliminary study, 
a timed dehydration test was carried out. MBCDFLU dehydrated spontaneously in 12 
seconds while TBCDFLU was stable. In order to prevent the loss of water from MBCDFLU 
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and to obtain consistent results, all TGA experiments were carried out with the samples 
immersed in silicone oil. The percentage mass loss was 16.6% ± 1.6% for MBCDFLU and 
15.3% ± 0.8% for TBCDFLU. From 1H-NMR spectroscopic analysis of dissolved crystals the 
stoichiometric ratio CD:API for the two complexes was established as 2:1. With this 
information, it was possible to determine the chemical formulae for the two complexes, 
namely (C42H70O35)2 ∙ C13H12ON6F2 ∙ 21.3 H2O for MBCDFLU and (C42H70O35)2 ∙ C13H12ON6F2 
∙ 27.3 H2O for TBCDFLU. It was thus possible to confirm the distinct nature of the two crystal 
forms in terms of their molecular and crystal structures, water contents and tendencies for 
dehydration. Following dehydration, the final degradation temperatures of the resulting 
anhydrous complexes were also different, namely 308 °C and 320 °C respectively. A phase 
solubility study was performed according to the method described by Higuchi and Connors3 
to determine the formation constant of the complex in solution. A value of 27.2 M-1 was 
obtained. 
In the literature a similar case to that found with TBCDFLU and MBCDFLU was reported 
previously: a methylparaben molecule was included in β-CD and two structurally different 
complexes were isolated.4 It is remarkable that the procedures of isolation and the structures 
of the crystals are very similar to those for the fluconazole complexes, described in this 
dissertation. The latter complexes may be considered more relevant for two reasons. The 
first is the potential pharmaceutical application: fluconazole is a common antifungal drug, 
whereas methylparaben is an excipient used in drug and other formulations. The second 
reason relates to the operational time for isolating the crystals: in the paper describing the 
methylparaben complexes4 the times varied from one week to one month, whereas in the 
case of the fluconazole complexes, it was possible to isolate both forms in 2-3 days. 
The third and last complex of fluconazole was obtained with γ-CD as host. The preparative 
procedure was the same as that for the β-CD complex. The single crystal obtained was 
subjected to X-ray analysis and was found to be tetragonal (space group P4212). The refined 
model comprised the host molecules and water molecules only, because it was impossible to 
find the significant difference electron density peaks of the guest inside the cavities of the 
host molecules (a common occurrence with γ-CD complexes). The crystal packing was 
organized in channels constructed from repeating units of three stacked crystallographically 
independent host molecules. The thermal analysis with HSM indicated the degradation 
point at 278 °C. The water mass loss of a sample analysed by TGA was 15.0 % ± 0.5 %. The 
stoichiometric ratio between the CD and the API, determined by 1H-NMR spectroscopic 
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analysis, was found to be 1:1. The combined data yielded the chemical formula for the 
complex, namely C48H80O40 ∙ C13H12F2N6O ∙ 16H2O. 
7.3) FUTURE WORK 
Due to the lack of time phase solubility studies were carried out with fluconazole and only 
one cyclodextrin, namely β-CD. In the future, more extensive phase solubility experiments 
using a wide variety of CD hosts are envisaged. Further tasks would include also the 
completion of the refinement of the MBCDFLU model by the addition of hydrogen atoms to 
the water molecules and the drafting of a manuscript for publication on the topic presented 
in Chapter 5. 
Although the GCDFLU X-ray model is incomplete due to severe guest disorder, the inclusion 
complex is nevertheless well characterized chemically, and from a pharmaceutical point of 
view the results obtained are very valuable for possible applications in drug delivery. In 
future, further assessment (e.g. solubility and stability measurements, bioavailability 
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Figure A1: 1H-NMR spectrum of pure -CD in DMSO-d6. 
 
Table A1: 1H-NMR integration peaks for pure -CD. 
Proton δ (ppm) Multiplicity J (Hz) Integration 
Experimental/ 
Theoretical 
H8 5.67-5.76 d (x 2) 2.1; 5.1 16.20 1.01 
H1 4.87-4.92 d 2.7 8.00* 1.00 
H7 4.45-4.52 t 2.1 8.06 1.01 
H3, H5, H6 3.51-3.68 m / 32.22 1.01 





Figure A2: 1H-NMR spectrum of pure I-SSZ in DMSO-d6. 
 
Table A2: 1H-NMR integration peaks for pure I-SSZ. 
Proton δ (ppm) Multiplicity J (Hz) Integration 
Experimental/ 
Theoretical 
HH 8.35-8.38 d 1.8 1.00* 1.00 
HA, HF, HG, HI, HL 7.93-8.12 m / 6.61 0.94 
HC 7.74-7.80 m / 1.13 1.13 
HE 7.22-7.27 d 3.3 1.04 1.04 
HD 7.15-7.19 d 6.6 1.09 1.09 
HB 6.85-6.91 m / 1.07 1.07 
*reference integral 
 
 
